CN115746023A - 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 - Google Patents
一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 Download PDFInfo
- Publication number
- CN115746023A CN115746023A CN202211323247.8A CN202211323247A CN115746023A CN 115746023 A CN115746023 A CN 115746023A CN 202211323247 A CN202211323247 A CN 202211323247A CN 115746023 A CN115746023 A CN 115746023A
- Authority
- CN
- China
- Prior art keywords
- cancer
- synthesis
- nmr
- 400mhz
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 heterocyclic macrocyclic compound Chemical class 0.000 title claims abstract description 202
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 229940043355 kinase inhibitor Drugs 0.000 title abstract description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 title abstract description 3
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 229940002612 prodrug Drugs 0.000 claims abstract description 20
- 239000000651 prodrug Substances 0.000 claims abstract description 20
- 239000012453 solvate Substances 0.000 claims abstract description 20
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 6
- 208000035475 disorder Diseases 0.000 claims abstract description 5
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- 230000003213 activating effect Effects 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 3
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims abstract description 3
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 3
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims abstract description 3
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 3
- 206010018338 Glioma Diseases 0.000 claims abstract description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract description 3
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims abstract description 3
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 3
- 206010027406 Mesothelioma Diseases 0.000 claims abstract description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims abstract description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 3
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 3
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 3
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims abstract description 3
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims abstract description 3
- 208000005017 glioblastoma Diseases 0.000 claims abstract description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 3
- 201000010982 kidney cancer Diseases 0.000 claims abstract description 3
- 208000032839 leukemia Diseases 0.000 claims abstract description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 3
- 201000001441 melanoma Diseases 0.000 claims abstract description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 3
- 201000002510 thyroid cancer Diseases 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 6
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 6
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000003003 spiro group Chemical group 0.000 claims description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims 1
- 230000004927 fusion Effects 0.000 abstract description 15
- 230000035772 mutation Effects 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 description 196
- 238000003786 synthesis reaction Methods 0.000 description 196
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 180
- 238000000034 method Methods 0.000 description 145
- 239000007787 solid Substances 0.000 description 124
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 120
- 238000006243 chemical reaction Methods 0.000 description 25
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 23
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 239000012043 crude product Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 150000002678 macrocyclic compounds Chemical class 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229960005061 crizotinib Drugs 0.000 description 4
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 4
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 101150023956 ALK gene Proteins 0.000 description 3
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 3
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- OLKIYJDSLMKNLC-UHFFFAOYSA-N (3-cyano-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(C#N)=C1 OLKIYJDSLMKNLC-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 1
- DPVIABCMTHHTGB-UHFFFAOYSA-N 2,4,6-trichloropyrimidine Chemical compound ClC1=CC(Cl)=NC(Cl)=N1 DPVIABCMTHHTGB-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- MGGVALXERJRIRO-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-2-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-1H-pyrazol-5-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)O MGGVALXERJRIRO-UHFFFAOYSA-N 0.000 description 1
- GKQDDKKGDIVDAG-UHFFFAOYSA-N 4-fluoro-2-methylphenol Chemical compound CC1=CC(F)=CC=C1O GKQDDKKGDIVDAG-UHFFFAOYSA-N 0.000 description 1
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 1
- GLYMPHUVMRFTFV-QLFBSQMISA-N 6-amino-5-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-n-[4-[(3r,5s)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NN=1)N)=CC=1C(=O)NC(C=C1)=CC=C1C(=O)N1C[C@H](C)N[C@H](C)C1 GLYMPHUVMRFTFV-QLFBSQMISA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000016718 Chromosome Inversion Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- ZBKDTSBHONTTIO-UHFFFAOYSA-N [4-(4-methylpiperazin-1-yl)phenoxy]boronic acid Chemical compound C1CN(C)CCN1C1=CC=C(OB(O)O)C=C1 ZBKDTSBHONTTIO-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229950004272 brigatinib Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950004126 ensartinib Drugs 0.000 description 1
- 229950000521 entrectinib Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229950001290 lorlatinib Drugs 0.000 description 1
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- SUZTYHAYMOGMQP-UHFFFAOYSA-N tert-butyl N-[2-(4-fluoro-2-methylphenoxy)ethyl]carbamate Chemical compound FC1=CC(=C(OCCNC(OC(C)(C)C)=O)C=C1)C SUZTYHAYMOGMQP-UHFFFAOYSA-N 0.000 description 1
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于制药领域,涉及一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法,该化合物具有通式(I)。本发明还涉及该化合物在药学上可接受的盐类,前药和溶剂化物。本发明还涉及在制备治疗或预防由激活或抗性突变体形式的ALK等靶点介导的障碍或疾病的药物中的用途,优选地,所述激活或抗性突变体形式(包含但不限于EML4‑ALK融合突变)的ALK介导的障碍或疾病为肺癌,卵巢癌、宫颈癌、结肠直肠癌、乳腺癌、胰腺癌、胶质瘤、胶质母细胞瘤、黑色素瘤、前列腺癌、白血病、淋巴瘤、非霍奇金淋巴瘤、胃癌、肺癌、肝细胞癌、胃肠道基质瘤、甲状腺癌、胆管癌、子宫内膜癌、肾癌、间变性大细胞淋巴癌、急性髓细胞白血病、多发性骨髓瘤或间皮瘤等。
Description
技术领域
本发明属于制药领域,涉及多种蛋白激酶的多靶点抑制剂及其制备方法与应用。
背景技术
蛋白激酶在机体内的多方面都起着举足轻重的作用,它们控制细胞的新陈代谢、转录、分裂、运动和细胞程序性死亡,它们也参与免疫反应和神经系统功能。蛋白激酶涉及到的基因突变包括很多种,融合基因是其中的一种。
融合基因是从两个先前分开的基因形成的杂合基因。融合基因的产生主要有三种情况:易位、中间缺失,或染色体倒位。迄今为止,人们总共发现了超过10,861个癌症相关的融合基因突变,融合突变分布于几乎所有的癌症类型。
目前临床上,在所有融合突变中,有35%是与激酶相关的突变,由于激酶融合突变大多数是功能持续获得性突变,使得激酶融合突变成为一个有效的致癌突变指标和靶点。如 EML4-ALK、CD74-ROS1,KIF5B-RET相关的突变,FGFR2的融合突变,FGFR3,而另外一些融合突变则比较均匀的分布在不同的肿瘤类型,如BRAF、NTRK1、NTRK3等。
人源的间变性淋巴瘤激酶(ALK)基因座编码是经典的受体酪氨酸激酶(RTK),ALK融合突变最早报道于1999年变性大细胞淋巴瘤中的TPM3-ALK,直到发表在《Nature》上有关非小细胞肺癌EML4-ALK融合突变的报道才真正引起了人们的重视,开启了固体瘤融合突变靶向性药物研发的热潮。
随着科研人员对ALK基因融合的理解和基因测序技术的发展,ALK基因融合已经成为一个成熟又热门的靶点。从2011年克唑替尼被美国FDA批准作为一线用药治疗ALK阳性非小细胞肺癌以来,不断涌现新型小分子激酶抑制剂。这些小分子抑制剂不仅克服了克唑替尼的耐药性问题,而且延长了病人生存期并降低了药物的毒副作用。目前为止,已经开发出了一代,二代和三代小分子抑制剂。第一代主要以Crizotinib为代表,开启了ALK基因融合抑制剂的热潮;第二代主要是针对Crizotinib用药后产生的继发性耐药;目前应上市的药物有:Ceritinib,Alectinib,Brigatinib,第三代抑制剂包括:Lorlatinib,Entrectinib,Ensartinib,第三代抑制剂不仅要对一代和二代产生的继发性耐药有效,具有对ALK,NTRK1/2/3,ROS1,TRK,EGFR,FGFR等靶点的抑制活性,还必须对脑转移的病例有效,这就要求第三代的小分子具有CNS的相关性质。
发明内容
本发明的一个方面提供式(I)的环状化合物及其药学上可接受的盐、前药或溶剂化物,
其中
Z1,Z2,Z3分别独立地选自CH和N;优选地,Z1选自N,Z2选自N,Z3选自CH;或Z1选自CH,Z2选自N,Z3选自N。
n为1,2,3,4,5,6,7,8,9或10;优选地,n选自1,2,3,4。
X,Y,W分别独立地选自O,NH,NR4R5,S,C=O,CR4R5,R4和R5各自独立地选自氢、C1-C5烷基,C1-C5烷氧基;
R1选自H,卤素,NR6R7,CR6R7,含1-3个取代基的苯环,5-12元杂环,R6和R7各自独立地选自氢、C1-C5烷基;
所述5-12元杂环被C1-C10烷基、C1-C10烷氧基、C1-C10环烷基、C1-C10烷基酰胺,C1-C10环烷基酰胺、C1-C10烷基磺酰胺,C1-C10环烷基磺酰胺、氨基保护基、苯基、5-12 元杂环任选地取代;
R2,R3分别独立地选自氢,卤素,氨基,硝基,氰基,羟基,羧基,酰胺基,磺酸基,磺酰胺基,磺酸酯基,未取代的或取代的C1-C6烷基,未取代的或取代的C1-C6烷氧基,一取代或多取代的卤代烷基或烷氧基;
在某些实施例中,R2和R3分别独立选自H,F,Cl,Br,I;
在某些实施例中,R2为F,R3为H;或R2为Cl,R3为H;或R2为H,R3为F。
在一些实施例中,R1选自H,F,Cl,Br;
在一些实施例中,R1选自H或Cl;
在一些实施例中,R1选自NR6R7,CR6R7,,含1-3个取代基的苯环,5-12元并环,5-12元螺环,5-12元桥环,R6和R7各自独立地选自氢、C1-C5烷基;
所述5-12元并环、螺环和桥环被C1-C10烷基、C1-C10烷氧基、C1-C10环烷基、C1-C10 烷基酰胺,C1-C10环烷基酰胺、C1-C10烷基磺酰胺,C1-C10环烷基磺酰胺、氨基保护基、苯基、5-12元杂环任选地取代;
在一些实施例中,R1选自以下通式:
其中m’,n’,m”和n”分别独立地选自1,2,3,4,5;R选自C1-C10烷基, C3-C12环烷基,C1-C10烷基酰胺,C1-C10环烷基酰胺,苯环,嘧啶,哌啶基,C1-C10烷基磺酰胺,C1-C10环烷基磺酰胺,氨基保护基;杂环可为饱和,部分饱和和不饱和,可为单环,并环,螺环,桥环,上述所有烷基可以是直链也可以是带支链的烷烃;
R选自H,O,CH3,CH2CH3,CH2CH2CH3,CH2CH2CH2CH3,CH(CH3)2,环丙基,环丁基,环戊基,环庚基,C1-C4烷基酰胺,C1-C6环烷基酰胺,苯环,嘧啶,哌啶基,C1-C6烷基磺酰胺,C1-C6环烷基磺酰胺,氨基保护基。
在一些实施例中,R1选自以下具体片段,
在某些实施例中,X与Y,W分别独立地选自CH2,NH,O。
在某些实施例中,X为CH2,Y为NH,W为O;通式如下:
在某些实施例中,R1为Cl,所述化合物选自:
本发明的另一个方面提供式I的化合物的制备方法:
提供一条式I通用的路线1
本发明的又一个方面提供包含式(I)化合物或其药学上可接受的盐、前药和溶剂化物的药用组合物。
本发明的再一个方面提供式(I)化合物或其药学上可接受的盐、前药和溶剂化物用于制造治疗哺乳动物的肿瘤、急性和慢性炎症疾病、炎症性肠道疾病、皮肤病、糖尿病、眼部疾病、与哺乳动物的血管发生或血管再生相关的疾病、与慢性疼痛相关的疾病、和其它由可以通过调控蛋白激酶来实现治疗的用途。
本发明的另一个方面提供式(I)化合物或其药学上可接受的盐、前药和溶剂化物在制备治疗或预防由激活或抗性突变体形式的ALK介导的障碍或疾病的药物中的用途,优选地,所述激活或抗性突变体形式的ALK介导的障碍或疾病为肺癌,卵巢癌、宫颈癌、结肠直肠癌、乳腺癌、胰腺癌、胶质瘤、胶质母细胞瘤、黑色素瘤、前列腺癌、白血病、淋巴瘤、非霍奇金淋巴瘤、胃癌、肺癌、肝细胞癌、胃肠道基质瘤、甲状腺癌、胆管癌、子宫内膜癌、肾癌、间变性大细胞淋巴癌、急性髓细胞白血病、多发性骨髓瘤或间皮瘤。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
如果没有另外指出,本发明全部公开内容采用以下术语定义:
所述的氢包括氢的各种同位素,如氘和氚。
术语“药学上可接受的盐”,除非另有说明,包括可存在于本发明化合物中的酸性基团的盐或碱性基团的盐。
所述烷基、烯基、炔基、环烷基部分可各自独立地被一个或多个选自以下的基团任选取代:羟基、氧代、卤素、氰基、硝基、三氟甲基、叠氮基、氨基、羧基、巯基。
饱和或不饱和烃基,例如烷基、烷二基或烯基,包括与杂原子的结合,例如烷氧基,均可以分别是直链或带有支链的。
实施例1-31的合成步骤:
第一步:合成(2-(4-氟-2-甲基苯氧基)乙基)氨基甲酸叔丁酯
在室温下,向4-氟-2-甲基苯酚(3.2g,25.4mmol),N-(叔丁氧羰基)乙醇胺(3.0 g,18.6mmol),三苯基膦(4.9g,18.6mmol)的THF(25mL)溶液中滴加偶氮二羧酸二异丙酯(3.8g,18.8mmol)。监测反应完全后,减压旋转蒸发除去有机溶剂,将所得固体在冷正己烷(25mL)的溶剂中打浆,过滤除去大部分三苯基膦氧化物副产物。然后减压旋蒸得到粗产品,通过快速正相色谱法(以PE/EA=1:10为洗脱液)纯化混合物,得到(2-(4-氟-2-甲基苯氧基)乙基)氨基甲酸叔丁酯(3.2g,产率:72%)为无色油状物。
1H NMR(400MHz,,CDCl3)δ7.17(s,1H),6.92(s,1H),6.70(s,2H),4.48(s, 1H),2.99(s,2H),2.48(s,2H),2.18(s,3H),1.55(s,2H),1.35(s,2H),1.31 (s,9H).
第二步:(2-(2-(溴甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯
向(2-(4-氟-2-甲基苯氧基)乙基)氨基甲酸叔丁酯(3.0g,14mmol)的四氯化碳(50mL)溶剂中分别加入NBS(2.9g,16.3mmoL)和AIBN(200mg,1.2mmoL),将该混合物加热回流过夜,监测反应原料完全反应后,冷却到室温,过滤后减压蒸除去有机溶剂得到粗产品,直接用正向柱层析(PE/EA为洗脱液)纯化,得到(2-(2-(溴甲基)-4- 氟苯氧基)乙基)氨基甲酸叔丁酯(3.0g,产率:63%)为黄色油状。
LC-MS(M+H+)249.1
1H NMR(400MHz,DMSO)δ6.89(d,J=38.1Hz,4H),3.86(s,2H),3.26(d,J =4.6Hz,2H),2.10(s,3H),1.33(s,9H).
第三步:合成(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯
向2(-2(溴甲基)--4-氟苯氧基)乙基)氨基甲酸叔丁酯(2.9g,8.35mmoL), (3-氰基-4-氟苯基)硼酸(2.1g,12.7mmoL)的THF(25mL)溶液中加入PdCl2(dppf) CH2Cl2的络合物(1.36g,1.67mmoL)和Cs2CO3(4.0g,12.3mmoL),将该反应混合物加热回流过夜,监测反应完全后,冷却到室温,过滤后减压旋蒸,再溶解到乙酸乙酯,分别用水,饱和食盐水洗涤,无水硫酸钠干燥后减压除去溶剂得到粗产品,直接用正向柱层析(PE/EA为洗脱液)纯化,得到(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基) 氨基甲酸叔丁酯(1.6g,产率:50%)为白色固体。
LC-MS(M+H+)289.3
1H NMR(400MHz,DMSO)δ7.79(t,J=7.5Hz,1H),7.45(d,J=10.6Hz,1H), 7.33(d,J=8.0Hz,1H),7.22–7.15(m,1H),7.06–6.90(m,4H),3.98(s,2H), 3.90(dd,J=13.7,8.6Hz,3H),3.32–3.27(m,2H),1.36(s,10H).
第四步:合成(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯
向(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(1.6g,4.1mmoL)的正丁醇(20mL)溶剂中加入水合肼(8mL),将该反应混合液加热至120℃并维持过夜,监测反应完全后,加入水(5mL)后减压旋蒸除去正丁醇,再分别用HCl(2N),饱和NaHCO3,水和饱和饱和食盐水洗涤,无水硫酸钠干燥后减压除去溶剂得到粗产品,直接用做下一步。
LCMS:401.3[M+1]+。
第五步:合成(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基) -4-氟苯氧基)乙基)氨基甲酸叔丁酯
向(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(500mg,1.25mmoL)和DIPEA(0.4mL,1.9mmoL)的DMF(10mL)溶剂中加2,4,6-三氯嘧啶(455mg,2.5mmoL),将该反应混合液在室温下搅拌过夜,监测反应完全后,将混合液倒入水(50mL),用乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥后减压旋蒸除去溶剂得到粗产品,直接用正向柱层析(PE/EA为洗脱液)纯化,得到(2-(2-((3- ((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(600mg,产率:87%)。
1H NMR(400MHz,DMSO)δ12.65(s,0H),11.10(s,0H),7.79(s,1H),7.64– 7.46(m,2H),7.33(s,1H),6.92(s,3H),3.90(q,J=11.6Hz,3H),3.06(s,2H), 2.11(d,J=10.1Hz,2H),1.32(d,J=10.5Hz,9H).
第六步:合成5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H- 吲唑-3-胺的三氟乙酸盐
向(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4氟苯氧基)乙基)氨基甲酸叔丁酯(600mg,1.09mmoL)的DCM(10mL)溶液中加入三氟乙酸(4 mL),在室温下搅拌4小时,监测反应原料完全转化后,直接减压旋蒸除去溶剂得到粗产品5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例1 12-氯-55-氟-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2) -苯并环壬基的合成,即大环环合物1。
将5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐(590mg,1.08mmoL)和K2CO3(450mg,3.26mmoL)的混合物加热到100℃并维持过夜,监测反应原料完全转化后,将混合液倒入水(50mL),用乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥后减压旋蒸除去溶剂得到粗产品,直接用反相柱层析 (Biotage的C18反相柱,以MeCN/0.05%的氨水为洗脱剂)纯化,得到目标化合物。大环环合物1为白色固体(60mg,收率:14%);
LC-MS(M+H+):411.1127
1H NMR(400MHz,DMSO-d6)δ12.39(s,1H),9.87(s,1H),7.32(s,1H),7.30 –7.24(m,3H),7.09(d,J=8.6Hz,1H),6.99(td,J=8.7,3.1Hz,1H),6.90(dd, J=9.0,4.7Hz,1H),6.05(s,1H),3.93–3.80(m,4H),3.37–3.34(m,2H), 3.30(m,2H)。
实施例2 16-氯-55-氟-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(2,4)-嘧啶-5(1,2) -苯并环壬基的合成
该化合物合成步骤与实施例1相同,是实施例1合成步骤中的另一终产物,与实施例1 为同分异构体
LC-MS(M+H+):411.1127
1H NMR(400MHz,DMSO)δ12.61(s,1H),9.64(s,1H),7.49(d,J=6.8Hz,1H), 7.40(d,J=8.6Hz,1H),7.27(d,J=8.7Hz,1H),7.20(dd,J=8.9,2.7Hz,1H), 7.07(ddd,J=11.6,8.8,4.0Hz,2H),6.82(s,1H),5.51(s,1H),4.11(s,2H), 3.98(s,2H),3.23(s,2H)。
实施例3大环环合物55-氟-12-吗啉代-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6) -嘧啶-5(1,2)-苯并环壬基的合成
将大环环合物12-氯-55-氟-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5 (1,2)-苯并环壬基(6mg,0.014mmoL)和对甲苯磺酸的一水合物(3mg,0.015mmoL) 的异丁醇(2mL)溶剂加热到120℃并维持3小时(微波加热),监测到反应原料完全转化为产物,直接将混合液用反相柱层析(Biotage的C18反相柱,以MeCN/0.05%的氨水为洗脱剂)纯化,得到目标化合物大环环合物55-氟-12-吗啉代-31H-6-氧杂-2,9-二氮杂-3 (3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯并环壬基(3mg,产率:47%)为白色固体,
LC-MS(M+H+):462.2045
1H NMR(400MHz,DMSO-d6)δ12.08(s,1H),9.07(s,1H),7.36(s,1H),7.17 (dd,J=14.4,8.5Hz,2H),7.00(d,J=8.5Hz,1H),6.91(t,J=7.5Hz,1H),6.81 (dd,J=8.8,4.7Hz,1H),5.34(s,1H),3.78(d,J=10.0Hz,4H),3.60(s,4H), 3.19(m,2H),2.59(dd,J=9.1,4.3Hz,2H)。
实施例4大环环合物55-氟-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5) -吲唑-1(4,6)-嘧啶-5(1,2)-苯环壬酮的合成
合成操作具体步骤参照实施例3,得到白色固体55-氟-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯环壬酮;
LC-MS(M+H+):475.2365,
1H NMR(400MHz,DMSO-d6)δ12.30(s,1H),9.87(s,1H),7.37(s,1H),7.26(d, J=9.4Hz,3H),7.10(s,1H),7.03–6.94(m,2H),6.88(dd,J=9.0,4.4Hz, 2H),5.52(s,1H),4.25(s,2H),3.86(d,J=22.2Hz,2H),3.16(m,br,4H),2.86 (m,br,7H)。
实施例5:大环环合物12-(4-乙基哌嗪-1-基)-55-氟-31H-6-氧杂-2,9-二氮杂-3(3,5) -吲唑-1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成操作具体步骤参照实施例3,得到大环12-(4-乙基哌嗪-1-基)-55-氟-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯环壬酮,白色固体;
LC-MS(M+H+):489.2518,
1H NMR(400MHz,DMSO-d6)δ12.30(s,1H),9.75(s,1H),9.14(s,1H),7.37 (s,1H),7.31–7.23(m,2H),7.10(s,1H),6.99(td,J=8.7,3.2Hz,1H),6.88 (dd,J=8.9,4.5Hz,1H),5.53(s,1H),4.26(s,2H),3.89(s,2H),3.84(s,2H), 3.60(d,J=10.4Hz,2H),3.44(m,2H),3.25–3.11(m,2H),3.05(s,2H),1.26 (t,J=7.3Hz,2H),1.20(t,J=7.3Hz,3H)。
实施例6大环环合物1-(4-(55-氟-31H-6-氧杂-2,9-氮杂-3(3,5)-吲唑-1(4,6)-
嘧啶-5(1,2)-苯环环壬基-12-基)哌嗪-1-乙酰基)-1-酮
合成操作具体步骤参照实施例3,得到大环化合物1-(4-(55-氟-31H-6-氧杂-2,9-氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯环环壬基-12-基)哌嗪-1-基)乙-1-酮,白色固体;
LC-MS(M+H+):503.2310
1H NMR(400MHz,DMSO-d6)δ12.44(s,1H),10.10(s,1H),8.78(s,1H),7.29 (s,3H),7.11(s,1H),7.05–6.96(m,1H),6.89(d,J=4.3Hz,1H),5.53(s,1H), 3.93(m,2H),3.85(s,2H),3.61(m,8H),3.09(d,J=29.3Hz,2H),2.06(s,3H)。
实施例7:大环环合物55-氟-12-(4-甲氧基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5) -吲唑-1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成操作具体步骤参照实施例3,得到55-氟-12-(4-甲氧基哌嗪-1-基)-31H-6-氧杂 -2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯环壬酮白色固体,
LC-MS(M+H+):490.2362,
1H NMR(400MHz,DMSO-d6)δ12.05(s,1H),8.96(s,1H),7.38(s,1H),7.21 –7.12(m,2H),7.00(d,J=8.5Hz,1H),6.90(td,J=8.8,3.0Hz,1H),6.81 (dd,J=8.9,4.7Hz,1H),6.13(s,1H),5.37(s,1H),3.78(m,3H),3.21(s,3H), 3.15(m,2H),3.04(t,J=10.0Hz,2H),2.62–2.56(m,2H),2.13(m,2H),1.81 (m,2H),1.36–1.27(m,2H)。
实施例8.55-氟-12-(4-联哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6) -嘧啶5(1,2)-苯环环壬基的合成
合成操作具体步骤参照实施例3,得到白色固体
LC-MS(M+H+)543.2995
1H NMR(400MHz,DMSO)δ12.11(s,1H),9.02(s,1H),7.44(s,1H),7.22(dd, J=18.0,8.5Hz,2H),7.06(d,J=8.4Hz,1H),7.01–6.93(m,1H),6.92–6.84 (m,1H),4.24(d,J=12.6Hz,2H),3.84(s,2H),3.16(s,1H),3.00(d,J=12.0 Hz,2H),2.69(d,J=14.0Hz,2H),2.26(s,2H),1.75(d,J=11.4Hz,2H),1.64 (d,J=12.0Hz,2H),1.48–1.45(m,4H),1.36(s,4H),1.23(s,2H).
实施例9 55-氟-12-(4-甲基-1,4-二氮杂-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)- 吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体
LC-MS(M+H+)489.2528
1H NMR(400MHz,DMSO)δ12.10(s,1H),9.00(s,1H),7.46(s,1H),7.23(dd, J=16.9,8.6Hz,2H),7.07(d,J=7.4Hz,1H),6.96(s,1H),6.87(s,1H),5.75 (d,J=5.1Hz,1H),5.29(d,J=4.9Hz,1H),3.84(s,4H),3.66(s,2H),3.50 (s,2H),3.40(s,3H),2.56(s,2H),2.29–2.21(m,4H),1.86(s,2H).
实施例10 55-氟-12-(4-环丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体
LC-MS(M+H+)501.2534
1H NMR(400MHz,DMSO)δ12.13(s,1H),9.04(s,1H),7.40(s,1H),7.24– 7.17(m,2H),7.06(s,1H),6.95(s,1H),6.84(d,J=4.9Hz,1H),6.33–6.04 (m,1H),5.40(s,1H),3.40(s,6H),2.56(s,4H),1.63(s,1H),0.49–0.33(m, 4H).0571
实施例11 55-氟-12-(4-甲基哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+)474.2419
1H NMR(400MHz,DMSO)δ12.12(s,1H),9.02(s,1H),7.59(d,J=25.8Hz, 3H),7.46(s,1H),7.24(s,2H),7.07(s,1H),6.92(d,J=33.9Hz,2H),5.48– 5.36(m,1H),4.19(s,2H),3.84(s,4H),3.41(s,2H),2.74(s,2H),1.63(s,2H), 1.38(s,3H),1.04–0.90(m,3H).0572
实施例12 55-氟-12-(4-乙酰基高哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+)517.2477
1H NMR(400MHz,DMSO)δ12.10(d,J=5.2Hz,1H),8.99(d,J=5.1Hz,1H), 7.44(dd,J=11.9,5.0Hz,1H),7.26–7.17(m,2H),7.06(s,1H),6.95(s,1H), 6.91–6.83(m,1H),5.75(d,J=5.1Hz,1H),5.34(d,J=5.0Hz,1H),3.84(s, 4H),3.73(s,1H),3.58(s,4H),3.49(s,1H),3.41(s,4H),1.98(d,J=22.2Hz, 3H),1.79(d,J=36.3Hz,2H).0573
实施例13 55-氟-12-(4-1,4-二氧杂-8-氮杂[4.5]癸烷-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+)518.2322
1H NMR(400MHz,DMSO)δ12.13(s,1H),9.06(s,1H),7.45(s,1H),7.29–7.20(m,2H),7.07(s,1H),6.97(s,1H),6.89(s,1H),6.27(s,1H),5.45(s,1H), 3.92(s,4H),3.89–3.82(m,4H),3.56(s,4H),3.41(s,2H),1.69–1.59(m, 4H).0574
实施例14 55-氟-12-(4-丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体.。
LC-MS(M+H+)503.2687
1H NMR(400MHz,DMSO)δ12.12(s,1H),9.08(s,1H),7.43(s,1H),7.22(dd, J=18.5,8.6Hz,2H),7.05(d,J=8.4Hz,1H),6.96(s,1H),6.87(s,1H),5.75 (d,J=3.5Hz,1H),5.39(s,1H),3.83(s,4H),3.41(s,6H),2.41(s,2H),2.27 (s,2H),1.48(s,2H),1.23(s,3H),0.87(s,4H).
实施例15 55-氟-12-(4-异丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体,
LC-MS(M+H+)503.2679
1H NMR(400MHz,DMSO)δ12.09(d,J=15.2Hz,1H),9.06(s,1H),8.61(s,1H), 7.39(d,J=25.5Hz,1H),7.25(s,2H),7.01(d,J=22.2Hz,2H),6.87(s,1H), 5.20(s,1H),3.85(s,4H),3.41(s,8H),3.16(s,1H),2.72(d,J=19.9Hz,2H), 0.99(d,J=6.1Hz,6H).0604
实施例16 55-氟-12-(4-3,9-二氮杂螺[5.5]十一烷-3-羧酸叔丁酯-1-基)-31H-6-氧杂 -2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+)629.3364
1H NMR(400MHz,DMSO)δ11.87(s,1H),8.79(s,1H),8.35(s,1H),7.14(s, 1H),6.99(d,J=20.9Hz,2H),6.82(s,1H),6.67(s,1H),4.98(s,-1H),3.59 (s,4H),3.27(s,10H),1.15(s,17H).
实施例17 55-氟-12-(4-丁基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+)517.2842
1H NMR(400MHz,DMSO)δ12.06(s,1H),9.05(s,1H),7.34(s,1H),7.19(s, 2H),6.91(d,J=51.4Hz,2H),5.18(s,1H),3.76(d,J=28.1Hz,8H),2.38(s, 8H),1.28(s,4H),0.93–0.75(m,3H).
实施例18 55-氟-12-(2-乙胺-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑-1(4,6) -嘧啶-5(1,2)-苯环十二烷
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+)448.2261
1H NMR(400MHz,DMSO)δ12.24(s,1H),9.73(s,1H),7.16–7.09(m,3H), 6.93(d,J=7.9Hz,1H),6.83(s,1H),6.75(s,1H),5.89(s,1H),3.71(d,J= 10.8Hz,4H),3.27(s,2H).
实施例19 55-氟-12-(4-(哌嗪)-嘧啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+):539.2430
1H NMR(400MHz,DMSO)δ12.15(s,1H),9.14(s,1H),8.40(t,J=4.6Hz,2H), 7.45(s,1H),7.22(dd,J=15.8,8.5Hz,2H),7.08(d,J=6.8Hz,1H),6.98(s, 1H),6.89(t,J=4.9Hz,1H),6.67(t,J=4.9Hz,1H),5.46(d,J=4.4Hz,1H), 3.83(s,8H),3.57(s,4H),3.43(s,2H).0608
实施例20 55-氟-12-(4-(甲基磺酰基)哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5) -吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+)539.1986
1H NMR(400MHz,DMSO)δ12.11(s,1H),9.03(s,1H),7.26(t,J=12.5Hz, 3H),7.07(d,J=9.2Hz,1H),6.98(s,1H),6.89(s,1H),6.18(s,1H),5.32(s, 1H),4.13(s,1H),3.84(d,J=10.0Hz,5H),3.18(d,J=4.9Hz,2H),2.97(s, 5H).
实施例21 55-氟-12-(4-(四氢喹啉)哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+)508.2261
1H NMR(400MHz,DMSO)δ12.15(d,J=15.4Hz,1H),7.45(d,J=23.3Hz,1H), 7.29(s,1H),7.24(s,5H),7.10(d,J=7.5Hz,1H),7.01(s,1H),6.91(s,1H), 4.69(s,2H),3.89(s,2H),3.79(s,2H),3.25(t,J=10.5Hz,2H),2.93(s,2H), 1.27(s,2H).
实施例22 55-氟-12-(3-甲基-3,9λ2-二氮杂螺[5.5]十一烷-1-基)-31H-6-氧杂-2,9- 二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+)543.2986
1H NMR(400MHz,CDCl3)δ7.94(s,1H),7.18(s,2H),7.01(s,1H),6.82(s, 1H),6.63(s,1H),5.92(d,J=20.5Hz,-1H),3.87(s,2H),3.62(s,1H),3.47 (s,2H),3.29(s,2H),2.46(s,3H),2.34(s,4H),1.65–1.59(m,4H),1.45(s, 4H),1.27–1.22(m,4H),0.84(s,2H).
实施例23 55-氟-12-(4-(苯基)哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+):536.2567
1H NMR(400MHz,DMSO)δ12.10(d,J=15.7Hz,1H),8.64(d,J=10.5Hz,1H), 7.43(d,J=24.7Hz,1H),7.32(d,J=7.3Hz,2H),7.25(s,1H),7.22–7.19 (m,2H),7.09(s,1H),6.98(s,1H),6.89(dd,J=8.9,4.7Hz,1H),5.28(s,1H), 3.82(s,3H),3.41(s,2H),2.81(s,4H),1.23(s,4H).
实施例24 55-氟-12-(4-(环己基)哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+):543.2990
1H NMR(400MHz,DMSO)δ11.90(s,1H),8.84(s,1H),7.20(s,1H),7.07– 6.93(m,2H),6.82(s,1H),6.72(s,1H),6.63(s,1H),5.15(s,1H),3.60(s,4H), 2.92(s,1H),2.44(s,2H),2.28(s,4H),2.17(s,2H),1.48(s,6H),0.95(s,6H).
实施例25 55-氟-12-(4-(环丙乙酰基)哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5) -吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体
LC-MS(M+H+):529.2475
1H NMR(400MHz,DMSO)δ11.87(s,1H),8.83(s,1H),7.12(s,1H),6.92(s, 2H),6.75(s,1H),6.65(s,1H),6.57(s,1H),6.00(s,1H),5.11(s,1H),3.53 (s,6H),3.22(s,4H),2.66(s,1H),0.46(s,4H).
实施例26 55-氟-12-(4-(环戊基)哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶5(1,2)-苯环环壬基
合成操作具体步骤参照实施例3,得到白色固体。
LC-MS(M+H+):529.2838
1H NMR(400MHz,DMSO)δ12.07(s,1H),9.03(s,1H),7.37(s,1H),7.16(d, J=19.8Hz,2H),7.00(s,1H),6.90(s,1H),6.81(s,1H),5.32(s,1H),3.76(s, 4H),2.61(s,2H),2.38(s,4H),2.25(s,5H),1.61(d,J=51.1Hz,4H),1.28(s, 4H).
实施例27 12-(4-甲基哌嗪苯基-1-基)-55-氟-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
氮气保护下,将20mg大环原料,30mg(4-(4-甲基哌嗪-1-基)苯基)硼酸,碳酸钾,4(三苯基膦)钯溶于5mL THF中,加入几滴水,随后回流反应6小时,降到室温后,直接加硅胶旋干,过柱得到白色产物。
LC-MS(M+H+):551.2363
1H NMR(400MHz,DMSO)δ12.23(d,J=20.2Hz,1H),9.57(s,1H),7.23(s, 9H),6.46(s,-1H),4.19(s,2H),3.92(s,2H),3.80(s,2H),3.60(s,-2H),2.87 (s,6H).
实施例28:大环化合物55-氟-16-(4-吗啉-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)- 吲唑-1(4,2)-嘧啶-5(1,2)-苯环壬酮
合成操作具体步骤参照实施例3,得到白色固体,
LC-MS(M+H+):462.3,1H NMR(400MHz,DMSO-d6)δ12.72(s,1H),9.73–9.46 (m,1H),8.76(s,1H),7.42(d,J=8.7Hz,1H),7.30–7.22(m,3H),7.06–6.98 (m,3H),5.29(s,1H),4.14(s,2H),3.98(s,2H),3.78–3.74(m,2H),3.69(d, J=4.5Hz,2H),3.64(d,J=4.3Hz,2H),3.32(m,2H),3.11(m,2H)。
实施例29:55-氟-16-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,2)-嘧啶-5(1,2)-苯环壬酮
合成操作具体步骤参照实施例3,白色固体;
LC-MS(M+H+):475.3
1H NMR(400MHz,DMSO-d6)δ12.54(s,1H),9.81(s,1H),9.04(s,1H),7.38(d, J=8.6Hz,1H),7.24(t,J=9.0Hz,2H),7.07–6.98(m,3H),5.26(s,1H),4.62 (d,J=13.1Hz,2H),4.10(s,2H),3.96(s,2H),3.49(d,J=11.5Hz,2H),3.09 (d,J=42.3Hz,4H),2.84(s,3H)。
实施例30 55-氟-16-(4-甲酰基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,2)-嘧啶-5(1,2)-苯环壬酮
合成操作具体步骤参照实施例3,白色固体,
LC-MS(M+H+):503.2
1H NMR(400MHz,DMSO-d6)δ12.69(s,1H),9.77–9.59(m,1H),8.78(s,1H), 7.41(d,J=8.6Hz,1H),7.30–7.20(m,2H),7.06–6.98(m,4H),5.28(s,1H), 4.14(s,2H),3.98(s,2H),3.72(s,2H),3.35-3.57(m,6H),3.09(d,J=30.6Hz, 2H),2.06(m,3H)。
实施例31 55-氟-16-(4-甲氧基哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,2)-嘧啶-5(1,2)-苯环壬酮
合成操作具体步骤参照实施例3,白色固体,
LC-MS(M+H+):490.2,
1H NMR(400MHz,DMSO-d6)δ12.76(s,1H),9.87(s,1H),8.42(s,1H),7.43 (d,J=8.7Hz,1H),7.26(dd,J=13.7,8.9Hz,2H),7.07–6.97(m,3H),5.27 (s,1H),4.15(s,2H),3.99(m,5H),3.30(s,5H),3.05(d,J=57.1Hz,2H),1.91 (d,J=3.7Hz,2H),1.69–1.58(m,1H),1.52(d,J=6.8Hz,2H)。
实施例32-42的合成步骤:
第一步:合成(3-(5-氟-2-甲基苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(4-氟-2-甲基苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(3-(5-氟-2-甲基苯氧基)丙基)氨基甲酸叔丁酯为无色油状物。
1H NMR(400MHz,,CDCl3)δ6.81–6.69(m,2H),6.64(s,1H),4.11–3.97 (m,1H),3.90(d,J=5.4Hz,2H),3.26(s,2H),2.14(s,3H),1.95–1.87(m, 2H),1.36(s,9H).
第二步:合成(3-(2-(溴甲基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(2-(溴甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(3-(2-(溴甲基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯为黄色油状。
1H NMR(400MHz,,CDCl3)δ7.01(dd,J=8.4,3.0Hz,1H),6.98–6.89(m, 1H),6.78(d,J=4.0Hz,1H),4.96(s,1H),4.47(d,J=13.6Hz,2H),4.11– 3.95(m,2H),3.35(s,2H),2.01(s,2H),1.40(s,9H).
第三步:合成(3-(2-(3-氰基-4-氟苄基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到((3-(2-(3-氰基-4-氟苄基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯为白色固体。
1H NMR(400MHz,,CDCl3)δ7.72–7.29(m,3H),6.71(d,J=34.0Hz,3H), 4.96(s,1H),4.55(s,2H),4.07(s,2H),1.42(s,9H).
第四步:合成(3-(2-(((3-氨基-1H-吲唑-5-基)甲基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(3-(2-(((3-氨基-1H-吲唑-5-基)甲基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯为白色固体;LCMS:415.3[M+1]+。
第五步:合成(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基) -4-氟苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氟苯氧基)丙基)氨基甲酸叔丁酯(600mg,产率:87%)。
13C NMR(151MHz,DMSO)δ206.30,162.04,161.35,158.26,158.01,131.72,117.87,116.26,114.10,112.88,112.58,109.85,108.74,102.98,77.29,65.83,59.58,54.72,36.78,35.00,30.50,28.60,20.49,13.91.
1H NMR(400MHz,DMSO)δ12.69(s,1H),11.18(s,1H),7.95(d,J=2.0Hz, 1H),7.40(d,J=8.6Hz,1H),7.32(d,J=8.6Hz,1H),6.98(s,2H),6.85(s, 3H),5.76(d,J=2.0Hz,2H),3.97(s,2H),3.06(d,J=6.8Hz,2H),1.82(d, J=6.4Hz,2H),1.35(s,9H).
第六步:合成5-5-(2-(3-氨基丙氧基)-4-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐
参见5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐的合成,得到粗产品5-(2-(3-氨基丙氧基)-4-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例32:12-氯-55-氟-31H-6-氧杂-2,10-二氮杂3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2) -苯并环十烷:
合成步骤见实施例3,得到白色固体。
LC-MS(M+H+):425.1287
1H NMR(400MHz,DMSO)δ8.95(d,J=18.7Hz,1H),7.83(s,1H),7.73(s,1H), 7.34(s,1H),7.29–7.24(m,1H),6.99(s,2H),6.61(s,1H),6.38(s,2H),4.01 (s,4H),3.03(s,2H),2.27(d,J=41.9Hz,2H).
LC-MS(M+H+)425.1290
实施例33 55-氟-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环十二烷
合成步骤见实施例3,得到白色固体。
1H NMR(400MHz,dmso)δ12.20(s,1H),8.71(s,1H),7.21(s,3H),6.91(d, J=81.5Hz,3H),6.19(s,1H),5.73(d,J=23.6Hz,1H),5.34(d,J=22.5Hz, 1H),3.78(dd,J=61.8,22.3Hz,4H),2.82(s,2H),2.44(s,4H),2.32(d,J= 19.6Hz,4H),2.18(d,J=22.3Hz,3H),1.24(s,4H).
LC-MS(M+H+)489.2524
实施例34 55-氟-12-(4-乙基哌嗪-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环十二烷
合成步骤见实施例3,得到白色固体。
1H NMR(400MHz,CDCl3)δ9.83(s,1H),7.95(s,1H),7.06(s,3H),6.81(s, 1H),6.60(s,1H),5.18(s,1H),4.89(s,1H),3.86(s,4H),3.43(d,J=22.4Hz, 6H),2.87(dd,J=29.6,18.8Hz,2H),2.43(s,4H),1.97(s,2H),1.13(d,J= 61.0Hz,3H).
LC-MS(M+H+)503.2676
实施例35 55-氟-12-(4-吗啉-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑-1(4,6) -嘧啶-5(1,2)-苯环十二烷
合成步骤见实施例3,得白色固体。
1H NMR(400MHz,DMSO)δ12.20(s,1H),8.94(s,1H),7.53(s,1H),7.25(d, J=33.1Hz,2H),7.01(d,J=40.8Hz,2H),6.83(s,1H),6.12(s,1H),5.35(s, 1H),3.73(d,J=96.0Hz,10H),3.19(s,2H),1.78(s,2H).
LC-MS(M+H+)476.2185
实施例36 55-氟-12-(4-乙酰基哌嗪-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环十二烷
合成步骤见实施例3,得白色固体。
1H NMR(400MHz,DMSO)δ12.24(s,1H),8.98(s,1H),7.57(s,1H),7.28(d, J=31.1Hz,2H),7.04(d,J=42.5Hz,2H),6.85(s,1H),6.19(s,1H),5.41(d, J=4.7Hz,1H),3.88(d,J=11.9Hz,4H),3.52–3.43(m,6H),3.23(s,2H), 2.08–2.00(m,3H),1.82(s,2H).
LC-MS(M+H+)517.2470
实施例37 55-氟-12-(4-甲氧基哌啶-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环十二烷
合成步骤参见实施例3,得到白色固体。
1H NMR(400MHz,DMSO)δ12.22(s,1H),8.89(s,1H),7.59(s,1H),7.33(d, J=9.0Hz,1H),7.24(d,J=8.3Hz,1H),7.13(dd,J=32.7,8.1Hz,2H),6.99 (d,J=8.7Hz,1H),6.87(d,J=5.8Hz,1H),6.13(s,1H),5.43(s,1H),3.93 –3.81(m,6H),3.28(s,3H),3.24(s,2H),3.09(t,J=11.5Hz,2H),2.30(s, 1H),1.86(d,J=18.0Hz,4H),1.36(d,J=10.6Hz,2H).
LC-MS(M+H+)504.2515
实施例38 55-氟-12-(4-环丙基哌嗪-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环十二烷
合成步骤见实施例3,得到白色固体。
1H NMR(400MHz,DMSO)δ12.22(s,1H),8.92(s,1H),7.58(s,1H),7.43– 7.20(m,2H),7.09(d,J=8.5Hz,1H),7.00(d,J=9.8Hz,1H),6.87(s,1H), 6.14(s,1H),5.40(s,1H),3.89(s,4H),3.38(s,4H),3.23(s,2H),2.57(s,4H), 1.82(s,2H),1.64(s,1H),0.40(d,J=34.2Hz,4H).
LC-MS(M+H+)515.2679
实施例39 55-氟-12-(4-甲基高哌嗪-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环十二烷
合成步骤见实施例3,得到白色固体。
1H NMR(400MHz,DMSO)δ12.18(s,1H),8.83(s,1H),7.60(s,1H),7.32(s, 1H),7.23(d,J=7.9Hz,2H),7.19–7.03(m,2H),6.92(d,J=53.0Hz,2H), 6.03(s,1H),5.28(s,1H),3.88(s,4H),3.64(s,2H),3.49(s,2H),3.22(s,2H), 2.54(s,2H),2.29(s,2H),2.25(s,3H),1.83(s,4H),1.22(s,2H).
LC-MS(M+H+)503.2679
实施例40 55-氟-12-(4-1,4-二氧杂-8-氮杂[4.5]癸烷-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯环十二烷
合成步骤参考实施例3,得到白色固体。
1H NMR(400MHz,DMSO)δ12.16(s,1H),8.85(s,1H),7.53(s,1H),7.23(dd, J=34.7,9.8Hz,2H),6.98–6.92(m,1H),6.81(s,1H),6.11(s,1H),5.70(s, 1H),5.39(s,1H),3.85(d,J=10.9Hz,6H),3.50(s,3H),3.19–3.07(m,4H), 1.93(s,2H),1.78(s,2H),1.57(s,2H),1.24–1.08(m,2H).
LC-MS(M+H+)532.2471
实施例41 55-氟-12-(4-哌啶哌啶-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环十二烷
合成步骤见实施例3,得到白色固体。
1H NMR(400MHz,DMSO)δ12.00(s,1H),8.65(s,1H),7.36(s,1H),7.11(s, 1H),7.02(d,J=8.5Hz,1H),6.88(s,1H),6.77(s,1H),6.65(d,J=6.5Hz, 1H),5.54(s,2H),5.19(s,1H),4.01(d,J=12.8Hz,2H),3.67(s,4H),2.97(d, J=26.5Hz,4H),2.70(d,J=11.7Hz,2H),2.47(t,J=12.5Hz,3H),1.56(d, J=26.9Hz,2H),1.28–1.21(m,6H),1.14(s,4H).
LC-MS(M+H+)557.3152
实施例42 55-氟-12-(4-甲基哌啶-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环十二烷
合成步骤见实施例3,得到白色固体。
1H NMR(400MHz,DMSO)δ12.21(s,1H),8.87(s,1H),7.59(s,1H),7.38– 7.18(m,2H),7.04(dd,J=42.0,9.0Hz,2H),6.88(s,1H),6.10(s,1H),5.41 (s,1H),4.16(s,2H),3.87(d,J=14.9Hz,4H),3.22(s,2H),2.71(d,J=12.7 Hz,2H),1.86–1.74(m,2H),1.61(s,3H),1.04(d,J=13.5Hz,2H),0.92(d, J=6.1Hz,3H).
LC-MS(M+H+)488.2581
实施例43-53的合成步骤:
第一步:合成(2-(4-氟-2-甲基苯氧基)丁基)氨基甲酸叔丁酯
参见(2-(4-氟-2-甲基苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(4-氟-2-甲基苯氧基)丁基)氨基甲酸叔丁酯(3.2g,产率:47%)为无色油状物。
1H NMR(400MHz,,CDCl3)δ6.86–6.72(m,2H),6.73–6.63(m,1H),4.74 (s,1H),3.95–3.85(m,2H),3.17(s,2H),2.18(s,2H),1.80(t,J=7.2Hz, 2H),1.66(s,2H),1.43(s,9H).
第二步:合成(2-(2-(溴甲基)-4-氟苯氧基)丁基)氨基甲酸叔丁酯
参见(2-(2-(溴甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(溴甲基)-4-氟苯氧基)丁基)氨基甲酸叔丁酯(3.0g,产率:63%)为黄色油状。
1H NMR(400MHz,,CDCl3)δ6.95(s,1H),6.78–6.58(m,2H),4.36(s,1H), 4.01–3.76(m,2H),3.17(s,2H),2.07(s,2H),1.77(d,J=7.6Hz,2H),1.62 (s,2H),1.36(s,9H).
第三步:合成(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)丁基)氨基甲酸叔丁酯
参见(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)丁基)氨基甲酸叔丁酯(1.6g,产率:50%) 为白色固体。
1H NMR(400MHz,,CDCl3)δ7.45(t,J=7.0Hz,1H),7.02(d,J=7.7Hz,1H), 6.94(d,J=9.9Hz,1H),6.85(d,J=8.5Hz,1H),6.75(d,J=8.3Hz,1H),6.70 (dd,J=8.4,4.1Hz,1H),3.90(s,2H),3.84(s,2H),3.07(s,2H),1.70–1.62 (m,2H),1.52–1.44(m,2H),1.37(s,9H).
第四步:合成(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)丁基)氨基甲酸叔丁酯
参见(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)丁基)氨基甲酸叔丁酯为白色固体;LCMS:438.3[M+1]+。
第五步:合成(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基) -4-氟苯氧基)丁基)氨基甲酸叔丁酯
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氟苯氧基)丁基)氨基甲酸叔丁酯(600mg,产率:87%)。
1H NMR(400MHz,DMSO)δ12.67(s,1H),7.77(s,1H),7.37(d,J=8.3Hz,1H), 7.27(s,1H),6.94(d,J=10.1Hz,3H),6.80(s,1H),3.91(d,J=17.3Hz,4H), 2.88(d,J=9.5Hz,2H),1.63(s,2H),1.45(s,2H),1.33(s,9H).
第六步:合成5-(2-(2-氨基丁氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H- 吲唑-3-胺的三氟乙酸盐
参见5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐合成方法,得到粗产品5-(2-(2-氨基丁氧基)-5-氟苄基)-N-(2,6- 二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例43:12-氯-55-氟-31H-6-氧杂-2,11-二氮杂3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2) -苯并环戊烷
合成步骤详见实施例1,得到白色固体。熔点:
1H NMR(400MHz,DMSO)δ12.16(s,1H),8.67(s,1H),7.21(s,3H),6.98(s, 1H),6.78(d,J=34.3Hz,2H),6.17(s,1H),5.32(s,1H),3.84(s,2H),3.69(s, 2H),3.37(s,4H),2.80(s,2H),2.31(s,4H),2.17(s,3H),1.23(d,J=37.2Hz, 4H).
LC-MS(M+H+)439.1444
实施例44:55-氟-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):503.2683
1H NMR(400MHz,DMSO)δ12.16(s,1H),8.67(s,1H),7.21(s,3H),6.98(s, 1H),6.78(d,J=34.3Hz,2H),6.17(s,1H),5.32(s,1H),3.84(s,2H),3.69(s, 2H),3.37(s,4H),2.80(s,2H),2.31(s,4H),2.17(s,3H),1.23(d,J=37.2Hz, 4H).
实施例45:55-氟-12-(4-乙基哌嗪-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。熔点:
LC-MS(M+H+):517.2839
1H NMR(400MHz,DMSO)δ11.96(s,1H),8.47(s,1H),7.01(s,3H),6.78(s, 1H),6.63(s,1H),6.54(s,1H),5.98(s,1H),5.13(s,1H),3.65(s,4H),3.49 (s,4H),2.93(s,2H),2.61(s,2H),2.17(s,4H),0.78(s,3H).
实施例46:55-氟-12-(4-乙酰基哌嗪-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):531.2638
1H NMR(400MHz,DMSO)δ12.20(s,1H),8.74(s,1H),7.21(s,3H),7.01(s, 1H),6.84(d,J=9.0Hz,1H),6.74(s,1H),6.27(s,1H),5.37(s,1H),3.87(s, 2H),3.69(s,2H),3.49(s,4H),3.41(s,3H),2.87(s,2H),2.03(d,J=3.9Hz, 4H),1.22(s,4H).
实施例47:55-氟-12-(4-异丙基哌嗪-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):531.2997
1H NMR(400MHz,DMSO)δ12.32(s,1H),8.83(s,1H),7.43–7.29(m,3H), 7.15(s,1H),6.99(s,1H),6.90(s,1H),6.34(s,1H),5.49(s,1H),4.01(s,2H), 3.86(s,2H),3.63(s,2H),3.12(s,2H),2.97(s,2H),2.80(s,4H),2.46(s,1H), 1.47(s,4H),1.11(d,J=7.0Hz,6H).
实施例48:55-氟-12-(4-环丙基哌嗪-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):529.2851
1H NMR(400MHz,DMSO)δ12.20(s,1H),8.71(s,1H),7.58(d,J=24.9Hz, 3H),7.39(s,1H),7.23(s,2H),6.22(s,1H),3.95–3.66(m,4H),2.87(d,J =24.3Hz,4H),2.58(s,2H),1.81(s,1H),1.59(d,J=46.1Hz,2H),1.39(d, J=4.8Hz,4H),1.23(s,2H),0.40(d,J=33.7Hz,4H).
实施例49:55-氟-12-(4-吗啉-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,5)-吲唑-1(4,6) -嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):490.2373
1H NMR(400MHz,DMSO)δ12.23(s,1H),8.62(s,1H),7.64–7.58(m,3H), 7.42(s,1H),7.25(s,1H),6.91(d,J=36.6Hz,1H),4.00–3.64(m,6H),2.78 (d,J=71.0Hz,2H),1.93–1.47(m,2H),1.41(q,J=5.7Hz,4H).
实施例50:55-氟-12-(4-甲氧基哌啶-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):518.2677
1H NMR(400MHz,DMSO)δ12.20(s,1H),8.67(d,J=6.4Hz,1H),7.31–7.19 (m,3H),7.06–6.98(m,1H),6.90–6.74(m,2H),6.20(s,1H),5.39(d,J= 6.1Hz,1H),3.90(s,3H),3.74(s,2H),3.20(d,J=18.7Hz,2H),3.10(d,J= 9.6Hz,2H),2.85(s,2H),2.55(s,1H),1.87(s,2H),1.38(d,J=11.9Hz,4H), 1.24(s,4H).
实施例51:55-氟-12-(4-1,4-二氧杂-8l2-氮杂螺[4.5]癸烷-1-基)-31H-6-氧杂-2,11- 二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):546.2622
1H NMR(400MHz,DMSO)δ12.21(s,1H),8.70(s,1H),7.24(dd,J=20.7,9.6 Hz,3H),7.03(s,1H),6.87(s,2H),6.23(s,1H),5.42(s,1H),3.93(d,J=3.1 Hz,4H),3.90(s,2H),3.74(s,2H),3.55(d,J=6.4Hz,4H),2.86(s,2H),1.62 (s,4H),1.33(s,2H),1.24(s,2H).
实施例52:55-氟-12-(4-甲基高哌嗪-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):517.2829
1H NMR(400MHz,DMSO)δ12.17(d,J=3.7Hz,1H),8.64(s,1H),7.29(s,1H), 7.21(d,J=15.7Hz,2H),7.02(s,1H),6.87(s,1H),5.26(s,1H),3.89(s,2H), 3.69(d,J=33.8Hz,3H),3.07(s,2H),2.84(s,2H),2.56(s,2H),2.27(s,4H), 1.86(s,2H),1.23(d,J=4.3Hz,6H).
实施例53:55-氟-12-(4-哌啶哌啶-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):571.3305
1H NMR(400MHz,DMSO)δ12.19(s,1H),8.66(s,1H),7.24(dd,J=19.5,9.7 Hz,3H),7.03(s,1H),6.87(s,1H),6.79(s,1H),6.19(s,1H),5.38(s,1H),4.25 (s,2H),3.89(s,2H),3.74(s,2H),3.18(d,J=8.6Hz,2H),2.99–2.81(m, 4H),2.70(s,2H),2.46–2.42(m,5H),1.76(s,2H),1.61(d,J=11.9Hz,2H), 1.47(s,4H),1.37(s,4H).
实施例54-64的合成步骤:
第一步:合成(2-(4-氯-2-甲基苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(4-氟-2-甲基苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(4-氯-2-甲基苯氧基)乙基)氨基甲酸叔丁酯(3.2g,产率:47%)为无色油状物。
1H NMR(400MHz,,CDCl3)δ7.13–6.94(m,2H),6.63(d,J=8.8Hz,1H), 4.86(s,1H),3.91(d,J=6.8Hz,2H),3.48(s,2H),2.13(s,3H),1.39(s,9H).
第二步:(2-(2-(溴甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-(溴甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(溴甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(3.0g,产率:63%)为黄色油状。
1H NMR(400MHz,,CDCl3)δ7.09(s,2H),6.69(d,J=8.3Hz,1H),4.99(s, 1H),3.96(d,J=5.1Hz,2H),3.54(d,J=6.8Hz,2H),2.18(s,3H),1.45(s, 9H).
第三步:合成(2-(2-(3-氰基-4-氯苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(3-氰基-4-氯苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(1.6g,产率:50%) 为白色固体。
1H NMR(400MHz,,CDCl3)δ7.42(s,2H),7.12(d,J=6.9Hz,1H),6.91(s, 1H),6.79(d,J=7.3Hz,2H),3.94(d,J=12.6Hz,4H),3.24(s,2H),2.13– 2.01(m,1H),1.92(s,2H),1.43(dd,J=3.3,1.7Hz,9H).
第四步:合成(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯为白色固体;LCMS:418.3[M+1]+。
第五步:合成(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基) -4-氯苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(600mg,产率:87%)。
1H NMR(400MHz,DMSO)δ12.69(s,1H),7.82(s,1H),7.34(s,2H),7.16(d, J=12.0Hz,2H),6.95(d,J=9.0Hz,1H),3.94(d,J=14.2Hz,4H),2.44(s, 2H),1.35(d,J=3.8Hz,9H).
第六步:合成5-(2-(2-氨基乙氧基)-5-氯苄基)-N-(2,6-二氯嘧啶-4-基)-1H- 吲唑-3-胺的三氟乙酸盐
参见5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐合成方法,得到粗产品5-(2-(2-氨基乙氧基)-5-氯苄基)-N-(2,6- 二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例54:12,55-二氯31H-6-氧杂-2,9-二氮杂3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯并环壬基
合成步骤详见实施例1,得到白色固体。
LC-MS(M+H+):426.0269
1H NMR(400MHz,DMSO)δ12.37(s,1H),9.86(s,1H),7.44(s,1H),7.31– 7.16(m,4H),7.05(s,1H),6.92(s,1H),6.02(s,1H),3.84(d,J=19.1Hz,4H), 3.37(s,2H).
实施例55:55-氯-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):491.2072
1H NMR(400MHz,DMSO)δ12.11(s,1H),9.10(s,1H),7.43(d,J=10.2Hz, 2H),7.25–7.17(m,2H),7.06(s,1H),6.91(d,J=8.7Hz,1H),6.25(s,1H), 5.40(s,1H),3.85(d,J=18.3Hz,4H),3.43(s,6H),2.36(s,4H),2.21(s,3H).
实施例56:55-氯-12-(4-乙酰基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):519.2023
1H NMR(400MHz,DMSO)δ12.22(s,1H),9.20(s,1H),7.53(d,J=9.7Hz,2H), 7.37–7.26(m,2H),7.14(d,J=9.0Hz,1H),7.00(d,J=9.1Hz,1H),6.35(s, 1H),5.50(s,1H),3.94(d,J=17.4Hz,4H),3.53(s,6H),2.55–2.48(m,4H), 2.46(s,2H),1.14(d,J=6.9Hz,3H).
实施例57:55-氯-12-(4-乙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):505.2231
1H NMR(400MHz,DMSO)δ12.22(s,1H),9.20(s,1H),7.53(d,J=9.7Hz,2H), 7.37–7.26(m,2H),7.14(d,J=9.0Hz,1H),7.00(d,J=9.1Hz,1H),6.35(s, 1H),5.50(s,1H),3.94(d,J=17.4Hz,4H),3.53(s,6H),2.55–2.48(m,4H), 2.46(s,2H),1.14(d,J=6.9Hz,3H).
实施例58:55-氯-12-(4-甲基高哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):505.2230
1H NMR(400MHz,DMSO)δ11.82(s,1H),8.75(s,1H),7.16(d,J=7.5Hz,2H), 6.96–6.88(m,2H),6.78(d,J=8.7Hz,1H),6.64(d,J=8.6Hz,1H),5.89(s, 1H),5.02(d,J=3.5Hz,1H),3.63–3.51(m,4H),3.39(s,2H),3.23(s,2H), 3.14(s,2H),2.90(s,1H),2.29(s,2H),2.00(s,3H),1.60(s,2H),0.96(s,1H).
实施例59:55-氯-12-(4-异丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):519.2380
1H NMR(400MHz,DMSO)δ12.08(s,1H),9.05(s,1H),7.43–7.37(m,2H), 7.17(d,J=8.3Hz,2H),7.01(d,J=8.6Hz,1H),6.87(d,J=8.9Hz,1H),5.36 (s,1H),3.81(d,J=18.0Hz,4H),3.38(s,8H),2.63(s,1H),0.98–0.93(m, 6H).
实施例60:55-氯-12-(4-环丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):517.2231
1H NMR(400MHz,DMSO)δ12.12(s,1H),9.09(d,J=4.3Hz,1H),7.44(dd, J=8.7,4.8Hz,2H),7.20(dt,J=8.7,4.5Hz,2H),7.04(d,J=8.5Hz,1H), 6.91(dd,J=8.9,4.6Hz,1H),5.40(d,J=4.2Hz,1H),3.84(d,J=17.8Hz, 4H),3.40(s,8H),2.58(d,J=5.9Hz,4H),1.23(d,J=4.6Hz,1H),0.44(d, J=6.4Hz,2H),0.36(s,2H).
实施例61:55-氯-12-(4-吗啉-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6) -嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):478.1756
1H NMR(400MHz,DMSO)δ12.10(s,1H),9.12(s,1H),7.40(d,J=11.9Hz, 2H),7.18(d,J=8.5Hz,2H),7.02(d,J=8.5Hz,1H),6.88(d,J=8.6Hz,1H), 5.37(s,1H),3.82(d,J=19.4Hz,4H),3.63(d,J=5.7Hz,4H),3.37(s,6H).
实施例62:55-氯-12-(4-甲基哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):490.2119
1H NMR(400MHz,DMSO)δ12.10(s,1H),9.02(s,1H),7.43(s,2H),7.29– 7.15(m,2H),7.05(d,J=9.6Hz,1H),6.90(d,J=9.6Hz,1H),6.20(s,1H), 5.40(s,1H),4.20(s,2H),3.84(d,J=18.6Hz,4H),2.87–2.62(m,3H),1.78 –1.47(m,4H),0.99(d,J=52.0Hz,7H).
实施例63:55-氯-12-(4-甲氧基哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):506.2071
1H NMR(400MHz,DMSO)δ12.12(s,1H),9.06(d,J=5.8Hz,1H),7.44(s,2H), 7.19(d,J=6.9Hz,2H),7.06(d,J=8.2Hz,1H),6.92(d,J=8.2Hz,1H),5.43 (d,J=6.8Hz,1H),3.85(d,J=17.1Hz,4H),3.42(s,3H),3.28(d,J=3.8Hz, 2H),3.17(d,J=6.1Hz,4H),2.90(d,J=12.3Hz,1H),1.47–1.14(m,4H).
实施例64:55-氯-12-(4-1,4-二氧杂-8l2-氮杂螺[4.5]癸烷-1-基)-31H-6-氧杂-2,9- 二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):534.2024
1H NMR(400MHz,DMSO)δ12.13(s,1H),9.04(s,1H),7.44(s,1H),7.21(s, 1H),7.02(s,2H),6.92(s,2H),6.27(s,1H),5.75(s,1H),3.94(d,J=7.0Hz, 6H),3.84(d,J=13.5Hz,4H),3.57(s,1H),2.15(s,4H),1.24(s,2H),1.17(s, 2H).
实施例65-75的合成步骤:
第一步:合成(2-(5-氟-2-甲基苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(4-氟-2-甲基苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(4-氯-2-甲基苯氧基)乙基)氨基甲酸叔丁酯(3.2g,产率:47%)为无色油状物。
1H NMR(400MHz,,CDCl3)δ7.03(q,J=6.7,5.9Hz,1H),6.50(s,2H),4.93 (s,1H),3.94(dq,J=11.5,5.4Hz,2H),3.52(d,J=16.1Hz,2H),2.15(d,J =4.2Hz,3H),1.44(d,J=4.2Hz,9H).
第二步:(2-(2-(溴甲基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-(溴甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(溴甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(3.0g,产率:63%)为黄色油状。
1H NMR(400MHz,CDCl3)δ7.26(d,J=3.2Hz,1H),7.19(d,J=8.2Hz,1H), 6.75(d,J=8.7Hz,1H),5.24(s,1H),4.45(s,2H),4.04(s,2H),3.56(s,2H), 1.42(s,9H).
第三步:合成(2-(2-(3-氰基-5-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(3-氰基-4-氯苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(1.6g,产率:50%) 为白色固体。
1H NMR(400MHz,CDCl3)δ7.41(s,2H),7.08(dt,J=20.1,8.1Hz,2H),6.54 (s,2H),4.79(s,1H),3.93(s,4H),3.45(s,2H),1.42(s,9H).
第四步:合成(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯为白色固体;LCMS:401.3[M+1]+。
第五步:合成(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基) -5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(600mg,产率:87%)。
1H NMR(400MHz,,CDCl3)δ12.46(s,1H),10.91(s,1H),7.57(s,1H),7.26 –7.08(m,1H),6.94(s,1H),6.78(d,J=21.9Hz,1H),6.64(s,1H),6.50(s, 1H),3.73(s,2H),1.15(s,9H).
第六步:合成5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H- 吲唑-3-胺的三氟乙酸盐
参见5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐合成方法,得到粗产品5-(2-(2-氨基乙氧基)-5-氯苄基)-N-(2,6- 二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例65:12,55-二氯31H-6-氧杂-2,9-二氮杂3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯并环壬基
合成步骤详见实施例1,得到白色固体。
LC-MS(M+H+):411.1129
1H NMR(400MHz,DMSO)δ12.48(s,1H),9.87(s,1H),7.27(s,4H),7.12(s, 1H),6.84(s,1H),6.68(s,1H),6.15–6.01(m,1H),3.86(d,J=30.5Hz,4H), 3.39(s,2H).
实施例66:55-氟-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):475.2369
1H NMR(400MHz,DMSO)δ11.94(s,1H),8.92(s,1H),7.19(d,J=14.7Hz, 2H),7.02(d,J=8.3Hz,1H),6.85(s,1H),6.63(d,J=11.3Hz,1H),6.52(s, 1H),6.03(s,1H),5.22(d,J=5.2Hz,1H),3.65(s,2H),3.26(s,3H),2.33(s, 4H),2.18(s,2H),2.04(s,2H),1.91(s,6H).
实施例67:55-氟-12-(4-乙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):489.2521
1H NMR(400MHz,DMSO)δ11.87(s,1H),8.86(s,1H),7.11(s,2H),6.93(s, 1H),6.78(d,J=8.2Hz,1H),6.60(s,1H),6.46(s,1H),6.03(s,1H),5.15(s, 1H),3.63(s,2H),3.56(s,2H),2.26(s,4H),2.15(d,J=17.9Hz,4H),0.80(s, 3H).
实施例68:55-氟-12-(4-异丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):503.2678
1H NMR(400MHz,DMSO)δ11.92(s,1H),9.01(s,1H),7.14(s,2H),7.00(d, J=8.0Hz,1H),6.83(s,1H),6.62(s,1H),6.53(s,1H),6.06(s,1H),5.21(d, J=7.2Hz,1H),3.69(s,2H),3.62(s,2H),3.30(s,4H),2.52(s,2H),2.31(s, 4H),1.71(d,J=6.2Hz,1H),0.80(d,J=22.6Hz,6H).
实施例69:55-氟-12-(4-甲基高哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):489.2520
1H NMR(400MHz,DMSO)δ11.82(s,1H),8.75(s,1H),7.11(d,J=23.4Hz, 2H),6.93(s,1H),6.76(s,1H),6.55(s,1H),6.41(s,1H),5.93(s,1H),5.02 (s,1H),3.62(s,2H),3.54(s,2H),2.24(s,8H),2.00(d,J=9.7Hz,4H),1.65 –1.59(m,3H).
实施例70:55-氟-12-(4-乙酰基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):503.2309
1H NMR(400MHz,DMSO)δ11.90(s,1H),8.92(d,J=5.9Hz,1H),7.15(d,J=11.6Hz,2H),6.98(d,J=7.4Hz,1H),6.80(d,J=8.3Hz,1H),6.59(d,J=8.4 Hz,1H),6.46(s,1H),6.11(s,1H),5.19(t,J=4.2Hz,1H),3.66(s,2H),3.58 (s,2H),3.30(s,4H),3.22(s,2H),2.28(d,J=5.7Hz,7H).
实施例71:55-氟-12-(4-乙酰基高哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):517.2472
1H NMR(400MHz,DMSO)δ11.87(s,1H),8.79(s,1H),7.15(d,J=15.5Hz, 2H),6.97(d,J=8.1Hz,1H),6.80(s,1H),6.60(s,1H),6.45(s,1H),6.16– 5.96(m,1H),5.54(d,J=7.3Hz,2H),3.72–3.48(m,4H),3.36(s,6H),2.55 (s,3H),1.83–1.72(m,4H),1.01(s,2H).
实施例72:55-氟-12-(4-环丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):501.2521
1H NMR(400MHz,DMSO)δ11.61(s,1H),8.61(d,J=19.6Hz,1H),6.89(s, 2H),6.71(s,1H),6.53(s,1H),6.33(s,1H),6.20(s,1H),5.81(s,1H),4.91 (d,J=19.7Hz,1H),3.33(d,J=28.9Hz,6H),2.76(s,4H),1.90(s,2H),1.68 –1.55(m,2H),1.17(s,1H),0.78(s,4H).
实施例73:55-氟-12-(4-吗啉-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6) -嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):462.2045
1H NMR(400MHz,dmso)δ11.70(s,1H),8.73(s,1H),6.95(s,2H),6.77(t, J=6.1Hz,1H),6.59(s,1H),6.44–6.35(m,1H),6.26(s,1H),4.96(d,J= 4.3Hz,1H),3.42(d,J=32.6Hz,4H),3.23(s,4H),2.97(s,8H).
实施例74:55-氟-12-(4-哌啶哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):543.2986
1H NMR(400MHz,DMSO)δ11.84(s,1H),8.79(s,1H),7.11(d,J=16.0Hz, 2H),6.94(d,J=8.4Hz,1H),6.76(s,1H),6.56(s,2H),6.42(s,1H),6.00(s, 1H),5.15(s,1H),4.00(s,1H),3.59(d,J=32.8Hz,4H),2.46(s,2H),1.81(d, J=4.5Hz,4H),1.18(d,J=44.9Hz,10H).
实施例75:55-氟-12-(4-甲氧基哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):490.2361
1H NMR(400MHz,DMSO)δ11.85(s,1H),8.80(s,1H),7.14(s,2H),6.94(d, J=8.2Hz,1H),6.77(s,1H),6.55(d,J=11.1Hz,2H),6.03(s,1H),5.17(s, 1H),3.59(d,J=34.7Hz,7H),3.02(s,3H),2.96(s,2H),2.34(s,2H),1.64(s, 2H),1.14(s,2H).
实施例76-86的合成步骤:
第一步:合成(2-(3-氟-5-甲基苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(5-氟-2-甲基苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(4-氯-2-甲基苯氧基)乙基)氨基甲酸叔丁酯(3.2g,产率:47%)为无色油状物。
1H NMR(400MHz,,CDCl3)δ6.30(s,2H),6.26–6.17(m,1H),4.90(s,1H), 3.78(t,J=5.0Hz,2H),3.32(s,2H),2.11(s,3H),1.27(s,9H).
第二步:合成(2-(3-(溴甲基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-(溴甲基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(溴甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(3.0g,产率:63%)为黄色油状。
11H NMR(400MHz,CDCl3)δ7.12(s,1H),6.44(s,1H),6.37(d,J=13.0Hz, 1H),4.94(s,1H),3.80(s,2H),3.38(s,2H),2.21(d,J=2.6Hz,2H),1.30(s, 9H).
第三步:合成(2-(3-(3-(3-氰基-4-氟苄基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(3-氰基-4-氯苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(1.6g,产率:50%) 为白色固体。
1H NMR(400MHz,,CDCl3)δ7.41(d,J=12.0Hz,2H),7.20(s,2H),6.56(s, 1H),6.48(d,J=11.3Hz,1H),3.95(s,2H),3.47(s,2H),2.55(s,1H),2.05(s, 2H),1.38(s,9H).0629
第四步:合成(2-(3-(((3-氨基-1H-吲唑-5-基)甲基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯为白色固体;LCMS:401.3[M+1]+。
第五步:合成(2-(3-((3-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(600mg,产率:87%)。
1H NMR(400MHz,DMSO)δ12.76(s,1H),11.28(s,1H),8.16(s,1H),7.48(s, 2H),7.26(s,1H),6.97(s,1H),3.95(s,2H),3.28–3.26(m,2H),2.43(s,2H), 2.11(s,2H),1.32(s,9H).
第六步:合成5-(3-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H- 吲唑-3-胺的三氟乙酸盐
参见5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐合成方法,得到粗产品5-(2-(2-氨基乙氧基)-5-氯苄基)-N-(2,6- 二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例76:12-氯-54-氟-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,2) -苯并环壬基
合成步骤详见实施例1,得到白色固体。
LC-MS(M+H+):411.1129
1H NMR(400MHz,DMSO)δ12.40(s,1H),9.76(s,1H),7.46(s,1H),7.30(s, 1H),7.21(s,2H),6.95(s,2H),6.69(s,1H),6.61(s,1H),5.85(s,1H),3.45 (s,2H),2.09(s,2H),1.99(s,2H).
实施例77:55-氟-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):475.2369
1H NMR(400MHz,CDCl3)δ10.68(s,1H),7.80(s,-1H),7.38(s,1H),6.67(s, 2H),5.30(s,1H),5.06(s,1H),3.83(s,2H),3.58–3.47(m,3H),2.33(s,4H), 0.89(s,2H).
实施例78:55-氟-12-(4-异丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例1,得到白色固体。
LC-MS(M+H+):503.2667
1H NMR(400MHz,CDCl3)δ9.85(s,-1H),7.91(s,1H),7.08(s,2H),6.64(d, J=30.4Hz,3H),5.32(d,J=17.4Hz,1H),3.82(s,2H),3.52(s,4H),3.11(s, 1H),2.56(s,4H),2.20(d,J=4.5Hz,4H),1.06(s,6H).
实施例79:55-氟-12-(4-乙酰基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):503.2318
1H NMR(400MHz,CDCl3)δ9.65(s,1H),7.83(s,1H),7.38(s,2H),7.14(s, 3H),6.57(s,1H),3.51(s,4H),2.23(s,3H),2.06(s,4H),1.19(s,4H).
实施例80:55-氟-12-(4-甲基高哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例1,得到白色固体。
LC-MS(M+H+):489.2511
1H NMR(400MHz,CDCl3)δ10.10(s,0H),7.96(s,1H),7.40(s,1H),7.22(s, 1H),7.04(s,1H),6.68(d,J=27.4Hz,2H),5.27(s,-1H),3.57(s,5H),2.73 (s,4H),2.43(s,6H),2.07(s,4H),1.33(s,2H).
实施例81:55-氟-12-(4-环丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):501.2525
1H NMR(400MHz,CDCl3)δ9.74(s,1H),7.87(d,J=26.5Hz,1H),6.98(s, 2H),6.64(s,1H),5.24(s,-1H),3.43(s,2H),3.15(s,1H),2.60(d,J=24.2 Hz,4H),2.17(d,J=20.9Hz,4H),1.29(s,4H),0.42(d,J=10.1Hz,4H).
实施例82:55-氟-12-(4-乙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):489.2523
1H NMR(400MHz,CDCl3)δ9.92(s,1H),7.80–7.75(m,1H),7.23(s,1H), 7.05(s,1H),6.97(s,1H),6.53(s,1H),6.47(s,1H),5.20(s,1H),4.82(s,1H), 3.68(s,4H),3.40(s,4H),2.37(s,4H),2.07(s,4H),1.00(d,J=6.5Hz,3H).
实施例83:55-氟-12-(4-哌啶哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):543.2993
1H NMR(400MHz,CDCl3)δ10.12(s,1H),8.00(s,1H),7.43(s,2H),6.73(s, 2H),6.49(s,1H),5.31(s,1H),5.05(s,1H),3.85(s,4H),3.61(s,4H),2.49 (s,10H),1.18(s,4H).
实施例84:55-氟-12-(4-乙酰基高哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1(4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):517.2471
1H NMR(400MHz,CDCl3)δ10.29(s,1H),7.92(s,1H),7.40(s,3H),6.42(d, J=10.0Hz,2H),5.25(s,1H),3.65(s,8H),2.72(s,3H),2.05(s,6H),1.07(d, J=140.4Hz,2H).
实施例85:55-氟-12-(4-丁基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑-1 (4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):517.2837
1H NMR(400MHz,CDCl3)δ9.68(s,1H),7.80(s,1H),7.35(s,2H),7.10(s, 2H),6.50(s,2H),5.37–5.15(m,1H),3.65(s,4H),3.40(s,4H),2.36(s,4H), 1.87(s,4H),1.39(s,3H),0.82(s,4H).
实施例86:55-氟-12-(4-甲磺酸哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,5)-吲唑 -1(4,6)-嘧啶-5(1,3)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):539.1981
1H NMR(400MHz,cdcl3)δ9.80(s,1H),7.84(s,1H),7.45(s,2H),7.34(s, 1H),7.09(s,1H),6.65(s,1H),6.47(s,1H),5.64(s,1H),3.92(s,4H),3.23 (s,4H),2.77(s,4H),2.30(s,3H),1.64(s,4H).
实施例87-95的合成步骤
合成(2-(3-(3-(4-氰基-3-氟苄基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(3-氰基-4-氯苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(1.6g,产率:50%) 为白色固体。
LC-MS(M+H+)289.3
1H NMR(400MHz,DMSO)δ7.79(t,J=7.5Hz,1H),7.45(d,J=10.6Hz,1H), 7.33(d,J=8.0Hz,1H),7.22–7.15(m,1H),7.06–6.90(m,4H),3.98(s,2H), 3.90(dd,J=13.7,8.6Hz,3H),3.32–3.27(m,2H),1.36(s,10H).
合成(2-(3-(((3-氨基-1H-吲唑-5-基)甲基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯为白色固体;LCMS:401.3[M+1]+。
第五步:合成(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基) -4-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(600mg,产率:87%)。
1H NMR(400MHz,DMSO)δ12.41(s,1H),7.66(s,2H),7.11(s,1H),6.89– 6.77(m,3H),6.73(td,J=9.4,8.8,3.9Hz,2H),3.79(s,2H),3.68(t,J=5.6 Hz,2H),1.12(d,J=5.9Hz,9H).
合成5-(3-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐
参见5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐合成方法,得到粗产品5-(2-(2-氨基乙氧基)-5-氯苄基)-N-(2,6- 二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例87:12-氯-55-氯-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑-1(4,6)-嘧啶-5(1,2) -苯并环壬基
合成步骤详见实施例1,得到白色固体。
LC-MS(M+H+):411.1127
1H NMR(400MHz,CDCl3)δ9.14(s,1H),7.41(s,1H),7.36(d,J=7.5Hz,1H), 7.10(d,J=7.8Hz,1H),6.94(d,J=7.4Hz,1H),6.76–6.66(m,2H),6.58(s, 1H),6.18(s,1H),6.01(s,1H),4.33(s,5H),4.33(s,4H),4.10–3.96(m,2H), 3.63(s,4H),2.07(s,3H),2.02(s,2H).
实施例88:55-氟-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
LC-MS(M+H+):475.2368
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):475.2368
1H NMR(400MHz,DMSO)δ9.37(s,1H),7.67(d,J=8.0Hz,1H),7.22(d,J =8.0Hz,1H),7.16(dd,J=9.2,3.1Hz,1H),7.11(dd,J=9.0,4.9Hz,1H),7.05 (s,1H),6.92–6.85(m,1H),6.13(d,J=5.2Hz,3H),3.58(s,7H),2.84(s, 7H),2.37–2.19(m,3H).
实施例89:55-氟-12-(4-甲氧基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):490.2362
1H NMR(400MHz,CDCl3)δ9.14(s,1H),7.41(s,1H),7.36(d,J=7.5Hz,1H), 7.10(d,J=7.8Hz,1H),6.94(d,J=7.4Hz,1H),6.76–6.66(m,2H),6.58(s, 1H),6.18(s,1H),6.01(s,1H),4.33(s,5H),4.33(s,4H),4.10–3.96(m,2H), 3.63(s,4H),2.07(s,3H),2.02(s,2H).
实施例90:55-氟-12-(4-乙酰基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):517.2465
1H NMR(400MHz,CDCl3)δ9.14(s,1H),7.41(s,1H),7.36(d,J=7.5Hz,1H), 7.10(d,J=7.8Hz,1H),6.94(d,J=7.4Hz,1H),6.76–6.66(m,2H),6.58(s, 1H),6.18(s,1H),6.01(s,1H),4.33(s,5H),4.33(s,4H),4.10–3.96(m,2H), 3.63(s,4H),2.07(s,3H),2.02(s,2H).
实施例91:55-氟-12-(4-哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑-1(4,6) -嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):474.2407
1H NMR(400MHz,CDCl3)δ9.04(s,1H),7.48(d,J=32.9Hz,1H),7.35(s, 2H),7.09(s,1H),6.99(s,2H),6.77(s,2H),6.21(s,1H),4.12(s,2H),3.49 (s,4H),2.37(s,1H),2.21(s,1H).
实施例92:55-氟-12-(4-异丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):503.2681
1H NMR(400MHz,CDCl3)δ9.54(s,1H),7.41(d,J=8.3Hz,1H),7.13(d,J =7.8Hz,1H),6.91(s,2H),6.76(s,1H),6.26(s,1H),5.07(s,1H),4.30(s, 2H),3.65(s,2H),3.48(s,2H),3.09(s,4H),2.59(s,4H),2.20(s,1H),1.08 (s,6H).
实施例93:55-氟-12-(4-高哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑-1(4,6) -嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):489.2526
1H NMR(400MHz,CDCl3)δ9.55(s,1H),7.40(s,1H),7.12(s,1H),6.91(s, 2H),6.77(s,1H),6.16(s,1H),5.01(s,1H),4.30(s,2H),3.81(s,2H),3.65 (s,2H),2.61(d,J=43.3Hz,4H),2.37(s,4H),2.01(s,3H),1.25(s,2H).
实施例94:55-氟-12-(4-环丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):501.2525
1H NMR(400MHz,CDCl3)δ9.55(s,1H),7.12(s,1H),6.91(s,2H),6.77(s, 1H),6.16(s,1H),5.01(s,1H),4.30(s,2H),3.81(s,2H),3.65(s,2H),2.61 (d,J=43.3Hz,4H),2.01(s,3H),1.25(s,2H).
实施例95:55-氟-12-(4-哌啶哌啶-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):543.2995
1H NMR(400MHz,CDCl3)δ9.40(s,1H),7.26(s,-1H),7.13(s,1H),6.81(s, 2H),6.62(s,2H),6.22(s,1H),4.17(s,4H),3.15(s,6H),2.57(s,5H),1.54 (s,10H).
实施例96-99的合成步骤:
合成(2-(3-(3-(4-氰基-3-氯苄基)-5-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(3-氰基-4-氯苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(1.6g,产率:50%) 为白色固体。
1H NMR(400MHz,,CDCl3)δ7.30(s,1H),7.26(d,J=2.3Hz,1H),7.19(s, 2H),7.11(s,1H),6.74(s,1H),4.78(s,1H),3.97(s,2H),3.52(s,2H),1.42 (s,9H).
合成(2-(3-(((3-氨基-1H-吲唑-5-基)甲基)-5-氯苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯为白色固体;LCMS:401.3[M+1]+。
合成(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(600mg,产率:87%)。
1H NMR(400MHz,,CDCl3)δ7.30(s,1H),7.26(d,J=2.3Hz,1H),7.19(s, 2H),7.11(s,1H),6.74(s,1H),4.78(s,1H),3.97(s,2H),3.52(s,2H),1.42 (s,9H).
合成5-(3-(2-氨基乙氧基)-5-氯苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐
参见5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐合成方法,得到粗产品5-(2-(2-氨基乙氧基)-5-氯苄基)-N-(2,6- 二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例96:12-氯-55-氟-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑-1(4,6)-嘧啶-5(1,2) -苯并环壬基
合成步骤详见实施例1,得到白色固体。
LC-MS(M+H+):427.0832
1H NMR(400MHz,DMSO)δ9.33(s,1H),7.95(s,1H),7.72(d,J=8.0Hz,1H), 7.34(s,1H),7.18(d,J=9.0Hz,2H),6.91(s,1H),6.61(s,1H),6.40(s,2H), 4.58(d,J=49.0Hz,2H),3.83(d,J=113.8Hz,4H).
实施例97:55-氯-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):491.2072
1H NMR(400MHz,CDCl3)δ9.56(s,1H),7.40(d,J=8.0Hz,1H),7.18(s,1H), 7.13(d,J=8.6Hz,2H),7.03(d,J=8.8Hz,1H),6.87(d,J=8.7Hz,1H),6.27 (s,1H),4.31(s,2H),3.77(s,2H),3.64(s,4H),2.45(s,4H),2.32(s,3H),2.17 (s,2H).
实施例98:55-氯-12-(4-乙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑-1 (4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):505.2231
1H NMR(400MHz,CDCl3)δ9.56(s,1H),7.40(d,J=8.1Hz,1H),7.18(s,1H), 7.12(d,J=8.3Hz,1H),7.03(d,J=8.5Hz,1H),6.87(d,J=8.7Hz,1H),6.26 (s,1H),4.31(s,2H),3.64(s,2H),3.37(s,2H),3.10(s,2H),2.45(s,4H),2.18 (d,J=8.3Hz,4H),1.11(s,3H).
实施例99:55-氯-12-(4-环丙基哌嗪-1-基)-31H-6-氧杂-2,9-二氮杂-3(3,6)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯环壬酮
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):517.2231
1H NMR(400MHz,CDCl3)δ9.56(s,1H),7.74(s,1H),7.42(s,1H),7.18(s, 2H),7.13(s,1H),7.03(s,1H),6.88(s,1H),6.26(s,1H),4.33(s,2H),3.71 (s,4H),3.59(s,2H),3.49(s,2H),2.65(s,6H).
实施例100-102的合成步骤
合成(2-(3-(3-(4-氰基-3-氟苄基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(3-氰基-4-氯苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(1.6g,产率:50%) 为白色固体。
1H NMR(400MHz,,CDCl3)δ7.45(t,J=7.0Hz,1H),7.02(d,J=7.7Hz,1H), 6.94(d,J=9.9Hz,1H),6.85(d,J=8.5Hz,1H),6.75(d,J=8.3Hz,1H),6.70 (dd,J=8.4,4.1Hz,1H),3.90(s,2H),3.84(s,2H),3.07(s,2H),1.70–1.62 (m,2H),1.52–1.44(m,2H),1.37(s,9H).
合成(2-(3-(((3-氨基-1H-吲唑-5-基)甲基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯为白色固体;LCMS:401.3[M+1]+。
合成(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(600mg,产率:87%)。
1H NMR(400MHz,CDCl3)δ7.76(s,1H),7.71(s,1H),7.53(s,1H),7.35(s, 1H),6.98(s,1H),6.86(s,1H),6.70(s,1H),4.00(s,2H),3.90(s,2H),3.56 (s,4H),2.04(s,4H),1.85(s,9H).
合成5-(3-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐
参见5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐合成方法,得到粗产品5-(2-(2-氨基乙氧基)-5-氯苄基)-N-(2,6- 二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例100:12-氯-55-氟-31H-6-氧杂-2,11-二氮杂3(3,6)-吲唑-1(4,6)-嘧啶-5(1,2)-苯并环戊环己烯
合成步骤详见实施例1,得到白色固体。
LC-MS(M+H+):439.1448
1H NMR(400MHz,DMSO)δ8.60(s,1H),7.92–7.75(m,2H),7.48(d,J=7.0 Hz,1H),7.34(d,J=7.5Hz,1H),6.92(s,2H),6.72(s,1H),6.39(s,2H),4.00 (s,3H),3.37(s,2H),1.94(s,5H).
实施例101:55-氟-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,6)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):503.2682
1H NMR(400MHz,CDCl3)δ8.85(s,1H),7.45(d,J=8.1Hz,1H),7.30–7.19 (m,2H),7.06(d,J=8.9Hz,1H),6.81–6.69(m,2H),6.36(s,1H),4.99(s, 1H),4.28(s,2H),4.01(s,2H),3.59(s,4H),3.38(s,2H),2.63(d,J=10.8Hz, 2H),2.05(d,J=38.6Hz,4H),1.11(d,J=7.9Hz,7H).
实施例102:55-氟-12-(4-乙基哌嗪-1-基)-31H-6-氧杂-2,11-二氮杂-3(3,6)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):517.2839
1H NMR(400MHz,CDCl3)δ8.85(s,1H),7.45(d,J=8.1Hz,1H),7.30–7.19 (m,2H),7.06(d,J=8.9Hz,1H),6.81–6.69(m,2H),6.36(s,1H),4.99(s, 1H),4.28(s,2H),4.01(s,2H),3.59(s,4H),3.38(s,2H),2.63(d,J=10.8Hz, 2H),2.05(d,J=38.6Hz,4H),1.11(d,J=7.9Hz,7H).
实施例103-106的合成步骤
合成(2-(3-(3-(4-氰基-3-氟苄基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(2-(3-氰基-4-氟苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-(3-氰基-4-氯苄基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯(1.6g,产率:50%) 为白色固体。
1H NMR(400MHz,,CDCl3)δ7.56–7.41(m,1H),6.82–6.73(m,2H),6.46 (s,1H),4.97(dt,J=12.3,6.2Hz,1H),4.85(s,1H),4.15(td,J=6.1,2.0Hz, 2H),3.36(t,J=5.4Hz,2H),2.08(q,J=6.3Hz,2H),1.44(s,9H),1.27(d, J=6.2Hz,9H).
合成(2-(3-(((3-氨基-1H-吲唑-5-基)甲基)-5-氟苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-氨基-1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯为白色固体;LCMS:425.3[M+1]+。
合成(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)丙基)氨基甲酸叔丁酯
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(600mg,产率:87%)。
参见(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基)-1H-吲唑-5-基)甲基)-4-氟苯氧基)乙基)氨基甲酸叔丁酯的合成,得到(2-(2-((3-((2,6-二氯嘧啶-4-基)氨基) -1H-吲唑-5-基)甲基)-4-氯苯氧基)乙基)氨基甲酸叔丁酯(600mg,产率:87%)。
1H NMR(400MHz,DMSO)δ12.57(s,1H),7.26(s,1H),7.02(s,1H),7.00(s, 1H),6.98(d,J=8.8Hz,1H),6.92(d,J=8.8Hz,1H),6.87(s,1H),4.00(s, 2H),3.91(s,2H),3.10(s,2H),1.98(s,1H),1.83(s,2H),1.36(s,9H).
合成5-(3-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐
参见5-(2-(2-氨基乙氧基)-5-氟苄基)-N-(2,6-二氯嘧啶-4-基)-1H-吲唑-3- 胺的三氟乙酸盐合成方法,得到粗产品5-(2-(2-氨基乙氧基)-5-氯苄基)-N-(2,6- 二氯嘧啶-4-基)-1H-吲唑-3-胺的三氟乙酸盐(592mg,产率:100%)。直接用于下一步反应。
实施例103:12-氯-55-氟-31H-6-氧杂-2,10-二氮杂3(3,6)-吲唑-1(4,6)-嘧啶-5(1,2)-苯并环戊环己烯
合成步骤详见实施例1,得到白色固体。
LC-MS(M+H+)425.1285
1H NMR(400MHz,DMSO)δ8.95(d,J=18.7Hz,1H),7.83(s,1H),7.73(s,1H), 7.34(s,1H),6.99(s,2H),6.61(s,1H),6.38(s,2H),4.01(s,4H),3.03(s,2H), 2.27(d,J=41.9Hz,2H).
实施例104:55-氟-12-(4-甲基哌嗪-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,6)-吲唑 -1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):489.2524
1H NMR(400MHz,CDCl3)δ9.23(s,1H),7.42(d,J=7.7Hz,1H),7.35(s,1H), 7.27(s,1H),7.15(d,J=8.1Hz,1H),7.02(s,1H),6.78(d,J=18.3Hz,2H), 6.26(s,1H),5.30(d,J=3.5Hz,4H),4.35(s,2H),4.12(d,J=7.2Hz,2H), 3.76(s,4H),2.62(t,J=1.1Hz,3H),2.44(s,2H),2.05(d,J=3.3Hz,2H).
实施例105:55-氟-12-(4-吗啉-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,6)-吲唑-1(4,6) -嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
1H NMR(400MHz,CDCl3)δ9.05(s,1H),7.45(d,J=7.7Hz,1H),7.00(s,2H), 6.82(s,1H),6.77(s,1H),6.66(s,1H),6.23(s,1H),5.30(s,1H),4.47(s,2H), 4.12(d,J=7.1Hz,2H),3.77(s,8H),2.05(s,2H).
实施例106:55-氟-12-(4-异丙基哌嗪-1-基)-31H-6-氧杂-2,10-二氮杂-3(3,6)-吲唑-1(4,6)-嘧啶-5(1,2)-苯甲环磷酰胺
合成步骤详见实施例3,得到白色固体。
LC-MS(M+H+):517.2839
1H NMR(400MHz,CDCl3)δ8.15(d,J=1.4Hz,1H),8.08(t,J=1.9Hz,1H), 8.02(s,1H),7.89(d,J=2.6Hz,1H),3.79(s,4H),3.59(s,2H),3.41(d,J= 5.1Hz,2H),3.23(s,1H),2.82(s,4H),2.59–2.50(m,4H),1.07(s,3H),1.06 (s,3H).
实施例107
性能测试1:ALK激酶抑制率实验
生物学实施例
ALK激酶抑制实验
Ⅰ流动性变化分析
1.制备用于检测激酶的1x激酶基缓冲液和停止缓冲液
1)1x激酶基缓冲液
50毫米HEPES,pH 7.5
0.0015% Brij-35
2)停止缓冲
100mm HEPES,pH 7.5
0.015% Brij-35
涂布试剂3号
50mM EDTA
2.复合准备
1)用100% DMSO将化合物稀释至最终所需的最高抑制剂浓度的50倍。将100μl的复合稀释液转移到96孔板的孔中。例如,若要求的抑制剂浓度为5μM,则在此步骤中配制复方DMSO溶液250μM,若要求的抑制剂浓度为0.1μM,则在此步骤中配制复方DMSO溶液5μM。
2)在同一96孔板的两个空孔中加入100μl 100% DMSO,无化合物对照和无酶对照。将印版标记为源印版。
3)制备中间板,将10μl的化合物从源板转移到新的96孔板作为中间板。在中间板各孔中加入90μl的1x激酶缓冲液。将混合物在中间板上搅拌10分钟。
3.准备试验板
1)将每孔5μl的样品从96孔中间板转移到384孔板中,一份一份。例如,将96孔板的A1转移到384孔板的A1和A2。9 6孔板的A2转移到384孔板的A3、A4,以此类推。
4.激酶反应
1)配制2.5倍酶溶液
在1x激酶基缓冲液中加入激酶。
2)配制2.5倍肽溶液
在1x激酶缓冲液中加入fam标记的肽和ATP。
3)实验板已含有5μL的化合物在10%的DMSO中。
4)转移2.5倍酶液到试验板
5)384孔试板每孔加10μl 2.5x酶液。
6)室温孵育10分钟。
7)转移2.5倍肽溶液到实验板
在384孔实验板的每孔中加入10μL的2.5x肽溶液。
8)激酶反应停止
在28℃下孵育一段时间。
加入25μL的停止缓冲液停止反应。
5.卡尺阅读
收集卡尺数据。
6.曲线拟合
1)从卡尺程序复制转换数据。
2)将转换值转换为抑制值。
抑制百分比=(max-conversion)/(max-min)*100。“max”代表DMSO控制;“min”代表低控制。
3)对XLFit excel插件5.4.0.8版本的数据进行拟合,得到IC50值。所用公式为:Y=Bottom+(Top-Bottom)/(1+(IC50/X)^HillSlope)
全部化合物1-15的IC50值如表所示。***代表IC50<100nmol,**代表100nmol<IC50<5000nmol,*代表IC50>5000nmol
表1 ALK激酶抑制率测试结果
***代表IC50<100nmol,**代表100nmol<IC50<5000nmol,*代表IC50>5000nmol
实施例108
性能测试2:H2228抑制率实验
细胞活性实验
1.细胞:NCI-H2228细胞,来自中国上海市睿智化学测试中心。
2.试剂:Gibco DMEM/F12培养基,Gibco 0.25%胰酶/EDTA细胞消化液,MTT(5mg/ml), DMSO,PBS。
3.仪器:37℃,5%CO2培养箱,TECAN InfiniteTM200系列多功能酶标仪,超净工作台,细胞计数板。
4.实验耗材:96孔板。
NCI-H2228细胞的活性测试实验步骤:
1.铺板。将处于对数生长期的细胞用消化液消化,新鲜培养基终止,对细胞进行计数,用新鲜培养基将细胞浓度调整到5*104个/ml,每孔加200μL,设调零孔(只加培养基)3个,其他边缘用无菌PBS填充。
2.于37℃下在5%CO2中孵育24小时,让细胞铺满孔底60%左右。
3.给药。将药物用DMSO溶解,配成10mmol/L母液,再用DMSO将其进行稀释,制成1mmol/L、100μmol/L、10μmol/L、1mol/L、0.1mol/L溶液,给药时,取上述浓度溶液1μL用培养基稀释成1mL,即给药浓度为10μmol/L、1μmol/L、100nmol/L、10nmol/L、 1nmol/L、0.1nmol/L、0nmol/L(对照组,加1μL DMSO用培养基稀释成1ml)。给药时,将原有孔内液体吸尽,加入含不同浓度药物的新鲜培养基,每孔200μl。
调零孔,只加培养基;
对照组,含与实验组相同体积的溶剂,用完全培养基稀释。每孔200μl;
实验组,将已溶解的药物用培养基稀释成0.1、1、10、100、1000、10000nM浓度,每孔200μl。
4.于37℃下在5%CO2中孵育。
5. 72h后,每孔加入20μL MTT溶液(5mg/ml),继续培养4h。
6.将96孔板用平板离心机离心,1000转/5分钟。
7.终止培养,小心吸去孔内的培养液。
8.每孔加入150μl二甲基亚砜(DMSO),低速震荡10min,待结晶物充分溶解后,在酶标仪,490nm波长处测其吸光值。
全部化合物的IC50值如表所示。***代表IC50<100nmol,**代表100nmol<IC50<5000nmol,*代表IC50>5000nmol
表2 H2228抑制率活性表
***代表IC50<100nmol,**代表100nmol<IC50<5000nmol,*代表IC50>5000nmol 。
Claims (16)
1.式(I)所示的化合物、其药学上可接受的盐、前药或溶剂化物,
其中
Z1,Z2,Z3分别独立地选自CH和N;
优选地,Z1选自N,Z2选自N,Z3选自CH;或Z1选自CH,Z2选自N,Z3选自N;
n为1,2,3,4,5,6,7,8,9或10;优选地,n选自1,2,3,4;
X,Y,W分别独立地选自O,NH,NR4R5,S,C=O,CR4R5,R4和R5各自独立地选自氢、C1-C5烷基,C1-C5烷氧基;
R1选自H,卤素,NR6R7,CR6R7,含1-3个取代基的苯环,5-12元杂环,R6和R7各自独立地选自氢、C1-C5烷基;
所述5-12元杂环被C1-C10烷基、C1-C10烷氧基、C1-C10环烷基、C1-C10烷基酰胺,C1-C10环烷基酰胺、C1-C10烷基磺酰胺,C1-C10环烷基磺酰胺、氨基保护基、苯基、5-12元杂环任选地取代;
R2,R3分别独立地选自氢,卤素,氨基,硝基,氰基,羟基,羧基,酰胺基,磺酸基,磺酰胺基,磺酸酯基,C1-C6烷基,C1-C6烷氧基。
2.根据权利要求1所示的化合物、其药学上可接受的盐、前药或溶剂化物,其中R1选自H,F,Cl,Br;优选地,R1选自H或Cl。
3.根据权利要求1所示的化合物、其药学上可接受的盐、前药或溶剂化物,其中R1选自NR6R7,CR6R7,,含1-3个取代基的苯环,5-12元并环,5-12元螺环,5-12元桥环,R6和R7各自独立地选自氢、C1-C5烷基;
所述5-12元并环、螺环和桥环被C1-C10烷基、C1-C10烷氧基、C1-C10环烷基、C1-C10烷基酰胺,C1-C10环烷基酰胺、C1-C10烷基磺酰胺,C1-C10环烷基磺酰胺、氨基保护基、苯基、5-12元杂环任选地取代。
9.根据权利要求1所示的化合物、其药学上可接受的盐、前药或溶剂化物,其中X与Y,W分别独立地选自CH2,NH,O。
11.根据权利要求1所示的化合物、其药学上可接受的盐、前药或溶剂化物,其中R2和R3分别独立选自H,F,Cl,Br,I。
12.根据权利要求1所示的化合物、其药学上可接受的盐、前药或溶剂化物,其中R2为F,R3为H;或R2为Cl,R3为H;或R2为H,R3为F。
15.权利要求1-14中任意一项所述化合物、其药学上可接受的盐、前药或溶剂化物在制备治疗或预防由激活或抗性突变体形式的ALK介导的障碍或疾病的药物中的用途;
优选地,所述激活或抗性突变体形式的ALK介导的障碍或疾病为肺癌,卵巢癌、宫颈癌、结肠直肠癌、乳腺癌、胰腺癌、胶质瘤、胶质母细胞瘤、黑色素瘤、前列腺癌、白血病、淋巴瘤、非霍奇金淋巴瘤、胃癌、肺癌、肝细胞癌、胃肠道基质瘤、甲状腺癌、胆管癌、子宫内膜癌、肾癌、间变性大细胞淋巴癌、急性髓细胞白血病、多发性骨髓瘤或间皮瘤。
16.一种药物组合物,所述的药物组合物包括治疗有效量的如权利要求1-14任意一项所述化合物、其药学上可接受的盐、前药或溶剂化物作为活性成分以及药学上可接受的载体或赋形剂。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211323247.8A CN115746023B (zh) | 2022-10-27 | 2022-10-27 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
PCT/CN2023/124971 WO2024088110A1 (zh) | 2022-10-27 | 2023-10-17 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211323247.8A CN115746023B (zh) | 2022-10-27 | 2022-10-27 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115746023A true CN115746023A (zh) | 2023-03-07 |
CN115746023B CN115746023B (zh) | 2024-08-09 |
Family
ID=85353573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211323247.8A Active CN115746023B (zh) | 2022-10-27 | 2022-10-27 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115746023B (zh) |
WO (1) | WO2024088110A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114805371A (zh) * | 2021-01-19 | 2022-07-29 | 江苏开元药业有限公司 | 含2-氨基嘧啶大环类化合物及其制备方法和用途 |
WO2024088110A1 (zh) * | 2022-10-27 | 2024-05-02 | 复旦大学 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026129A1 (en) * | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
WO2009013126A1 (en) * | 2007-07-20 | 2009-01-29 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
WO2009032668A2 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors |
WO2013132376A1 (en) * | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
US20160214996A1 (en) * | 2013-10-01 | 2016-07-28 | CS Pharmasciences, Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
WO2017004342A1 (en) * | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
CN109516999A (zh) * | 2017-11-01 | 2019-03-26 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
US20210171542A1 (en) * | 2018-04-16 | 2021-06-10 | Shenzhen Targetrx, Inc. | Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity |
CN114763360A (zh) * | 2021-01-15 | 2022-07-19 | 广州百霆医药科技有限公司 | 手性大环化合物作为蛋白激酶抑制剂及其用途 |
US20230183265A1 (en) * | 2020-05-08 | 2023-06-15 | Shandong Xuanzhu Pharma Co., Ltd. | Crystal Form of Macrocyclic Tyrosine Kinase Inhibitor and Preparation Method therefor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106866684B (zh) * | 2015-12-10 | 2020-06-09 | 吴耀东 | 用于治疗肿瘤的大环衍生物 |
CN111269245B (zh) * | 2018-12-04 | 2021-08-27 | 杭州百新生物医药科技有限公司 | 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途 |
CN113773335A (zh) * | 2019-06-21 | 2021-12-10 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 |
WO2022182845A1 (en) * | 2021-02-25 | 2022-09-01 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
US20240277714A1 (en) * | 2021-04-09 | 2024-08-22 | Revolution Medicines, Inc. | Use of sos1 inhibitors with ras inhibitors to treat cancers |
CN115746023B (zh) * | 2022-10-27 | 2024-08-09 | 复旦大学 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
-
2022
- 2022-10-27 CN CN202211323247.8A patent/CN115746023B/zh active Active
-
2023
- 2023-10-17 WO PCT/CN2023/124971 patent/WO2024088110A1/zh unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026129A1 (en) * | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
WO2009013126A1 (en) * | 2007-07-20 | 2009-01-29 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
WO2009032668A2 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors |
WO2013132376A1 (en) * | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
US20160214996A1 (en) * | 2013-10-01 | 2016-07-28 | CS Pharmasciences, Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
WO2017004342A1 (en) * | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
CN109516999A (zh) * | 2017-11-01 | 2019-03-26 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
US20210171542A1 (en) * | 2018-04-16 | 2021-06-10 | Shenzhen Targetrx, Inc. | Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity |
US20230183265A1 (en) * | 2020-05-08 | 2023-06-15 | Shandong Xuanzhu Pharma Co., Ltd. | Crystal Form of Macrocyclic Tyrosine Kinase Inhibitor and Preparation Method therefor |
CN114763360A (zh) * | 2021-01-15 | 2022-07-19 | 广州百霆医药科技有限公司 | 手性大环化合物作为蛋白激酶抑制剂及其用途 |
Non-Patent Citations (1)
Title |
---|
陈斌辉: "间变性淋巴瘤激酶(ALK)抑制剂的设计、合成、生物活性评价和类药性化合物库的构建", 《中国博士学位论文全文数据库》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114805371A (zh) * | 2021-01-19 | 2022-07-29 | 江苏开元药业有限公司 | 含2-氨基嘧啶大环类化合物及其制备方法和用途 |
CN114805371B (zh) * | 2021-01-19 | 2024-05-24 | 江苏开元药业有限公司 | 含2-氨基嘧啶大环类化合物及其制备方法和用途 |
WO2024088110A1 (zh) * | 2022-10-27 | 2024-05-02 | 复旦大学 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2024088110A1 (zh) | 2024-05-02 |
CN115746023B (zh) | 2024-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115746023B (zh) | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 | |
CN106883213B (zh) | 一种egfr和alk激酶的双重抑制剂 | |
AU2009222590B2 (en) | (3Z) -3-(hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | |
WO2017114383A1 (zh) | 一类新型的egfr野生型和突变型的激酶抑制剂 | |
Liu et al. | Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1, 2, 4-triazolone moiety as c-Met kinase inhibitors | |
TWI774758B (zh) | C5-苯胺喹唑啉化合物及其治療癌症之用途 | |
WO2007023768A1 (ja) | 新規ピリジン誘導体およびピリミジン誘導体(3) | |
WO2002032872A1 (en) | Nitrogenous aromatic ring compounds | |
WO2012061337A1 (en) | Fgfr2 modulators | |
CN103930425A (zh) | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 | |
ES2647849T3 (es) | Compuestos de pirido[2,3-d]pirimidin-4-ona como inhibidores de la tanquirasa | |
Zhou et al. | Design, synthesis and pharmacological evaluation of 6, 7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents | |
Zhou et al. | Design, synthesis and structure–activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents | |
CN105377835A (zh) | 酪氨酸蛋白激酶调节剂及其应用方法 | |
EP3371151A1 (en) | Compounds for treatment of cancer and epigenetics | |
TW201934546A (zh) | 嘧啶類化合物、其製備方法及其醫藥用途 | |
CN1863794B (zh) | 作为血管生成抑制剂的喹唑啉衍生物 | |
JP2019537598A (ja) | 2−多置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途 | |
ES2905985T3 (es) | Compuesto de oxazino-quinazolina y de tipo oxazino-quinazolina, método de preparación y usos de los mismos | |
CN111732548B (zh) | N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途 | |
Ye et al. | Design, synthesis and biological evaluation of novel 2, 4-bismorpholinothieno [3, 2-d] pyrimidine and 2-morpholinothieno [3, 2-d] pyrimidinone derivatives as potent antitumor agents | |
CN109970717A (zh) | 4-(脂肪环并嘧啶/吡啶取代)氨基-1h-3-吡唑甲酰胺类flt3抑制剂及其用途 | |
Ye et al. | Design, synthesis and biological evaluation of novel triazoloquinazolinone and imidazoquinazolinone derivatives as allosteric inhibitors of SHP2 phosphatase | |
Liu et al. | Identification of highly potent 2, 4‐diarylaminopyrimidine analogs of a typical piperidinyl‐4‐ol moiety as promising antitumor ALK inhibitors | |
Fu et al. | Design, synthesis, and biological evaluation of 2, 4-diaminopyrimidine derivatives as potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |